Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Prostate Cancer

Aliases
Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma, Prostatic Neoplasms, Recurrent Prostate Carcinoma (1 other aliases)

937 clinical trials

790 products

96 drugs

5 abstracts

Product
Apalutamide
Product
Androgen Deprivation Therapy
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Status: Active (not recruiting), Estimated PCD: 2024-04-22
Product
Placebo
Product
BMS-986218
Product
Docetaxel
Product
Nivolumab
Product
64Cu-SAR-bisPSMA
Product
67Cu-SAR-bisPSMA
Clinical trial
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Status: Recruiting, Estimated PCD: 2025-12-31
Product
CPI-0209
Clinical trial
A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Status: Completed, Estimated PCD: 2023-12-06
Product
[18F]CTT1057
Clinical trial
Phase II/III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging for the Detection of PSMA Positive Tumors Using Histopathology as a Standard of Truth
Status: Completed, Estimated PCD: 2023-11-24
Product
NGM831
Clinical trial
A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-01
Product
NGM831 and NGM438 plus pembrolizumab
Product
CT-0508
Clinical trial
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Status: Terminated, Estimated PCD: 2023-06-02
Product
Pembrolizumab
Product
Histrelin
Clinical trial
Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients With Advanced Prostate Cancer
Status: Completed, Estimated PCD: 2003-08-01
Clinical trial
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Status: Active (not recruiting), Estimated PCD: 2022-12-12
Product
PRL-02
Clinical trial
Phase 1/2a, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Product
dexamethasone
Clinical trial
A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase Ib/II Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Status: Recruiting, Estimated PCD: 2028-08-01
Product
177Lu-PSMA-I&T
Product
Abiraterone
Product
MDX2001
Product
prednisone
Product
PSMA-Targeted [In-111]-Labeled Trillium Compound
Product
PTI-122
Clinical trial
A Phase 0 Study of the Pharmacokinetics and Biodistribution of PSMA-Targeted [In-111]-Labeled Trillium Compounds With and Without PTI-122 in Patients With Metastatic Prostate Cancer to Inform Future Phase 1 Dosing With [Ac-225]-Trillium-PSMA Radionuclide Therapy
Status: Completed, Estimated PCD: 2023-12-12
Clinical trial
A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-08-01
Clinical trial
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Midazolam
Clinical trial
A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
Status: Active (not recruiting), Estimated PCD: 2023-01-31
Clinical trial
A LOng-term Follow-up Master Protocol for Participants Who Received Cell or Gene Therapies in Other AstraZeneca StUdieS (LOCUS)
Status: Not yet recruiting, Estimated PCD: 2041-11-29
Product
Enzalutamide
Product
Leuprolide
Product
AZD5851
Product
AZD0754
Product
ODM-208
Product
nivolumab
Clinical trial
A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2021-01-13
Clinical trial
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2019-08-30
Product
docetaxel
Product
enzalutamide
Product
rucaparib
Clinical trial
A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
ADT
Product
AMXI-5001
Clinical trial
An Open-Label Expanded Access Protocol for Apalutamide Treatment of Subjects With Non Metastatic Castration-Resistant Prostate Cancer
Status:
Product
ADXS31-142
Product
HC-1119
Clinical trial
PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Product
Ipilimumab
Product
Cabazitaxel
Clinical trial
A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2022-04-05
Product
Radium-223 dichloride
Product
Prednisone
Product
ODM-209
Clinical trial
A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Safety and Pharmacokinetics of ODM-209 in Patients With Metastatic Castration-resistant Prostate Cancer or Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer
Status: Completed, Estimated PCD: 2024-01-09
Product
ST101
Clinical trial
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-01
Product
IDE-161
Clinical trial
An Open-Label, Phase 1/2 Study to Evaluate Safety, Efficacy, and Pharmacokinetics of EU101, an Agonistic Anti-CD137 (4-1BB) Monoclonal Antibody in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-09-01
Product
EU101
Clinical trial
Treatment Satisfaction With Ra-223 Among Japanese Castration Resistant Prostate Cancer (CRPC) Patients
Status: Completed, Estimated PCD: 2022-12-01
Product
TT-00420
Clinical trial
Phase III, Open-Label Randomized, Parallel, Active-Control Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients With Metastatic Prostate Cancer
Status: Completed, Estimated PCD: 2001-12-01
Product
Zoladex
Clinical trial
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T Versus Hormone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Product
Atezolizumab
Product
Nab-Paclitaxel
Clinical trial
An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-08-27
Product
177Lu-rhPSMA-10.1
Product
NGM831 plus Pembrolizumab
Product
Temozolomide
Product
XNW5004
Clinical trial
Phase Ib, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN-509 in Combination With Abiraterone Acetate in Patients With Metastatic Castrate Resistant Prostate Cancer (CRPC)
Status: Completed, Estimated PCD: 2014-05-10
Product
ARN-509
Clinical trial
A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-08-01
Product
JANX007
Product
ONC-392
Clinical trial
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Multicentre, Open-label, Single-arm Study to Investigate the Efficacy and Safety of Triptorelin Pamoate 22.5 mg 6-month Formulation in Chinese Patients With Locally Advanced or Metastatic Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Product
Triptorelin pamoate
Product
CYH33
Clinical trial
A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)
Status: Completed, Estimated PCD: 2022-06-20
Clinical trial
Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Status: Terminated, Estimated PCD: 2023-02-15
Clinical trial
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Status: Terminated, Estimated PCD: 2023-05-04
Product
Novel hormonal therapy
Clinical trial
Novel Hormonal Therapies (NHTs) for the Treatment of Metastatic Castration-sensitive Prostate Cancer (mCSPC) in the Medicare Population
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Dexamethasone
Product
VERU-111
Clinical trial
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
Status: Recruiting, Estimated PCD: 2026-01-29
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)
Status: Completed, Estimated PCD: 2018-02-15
Product
Lorigerlimab
Product
VIO-01
Product
Matching placebo
Product
Prednisone/Prednisolone
Clinical trial
A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Product
FOR46
Product
NGM438
Clinical trial
A Phase 1 Study of FOR46 Administered Every 21 Days in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Completed, Estimated PCD: 2023-11-16
Clinical trial
TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Status: Active (not recruiting), Estimated PCD: 2025-09-18
Product
Talazoparib + Enzalutamide
Clinical trial
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2022-10-03
Product
177Lu-PSMA-617
Product
68Ga-PSMA-11
Product
ARDT
Clinical trial
An Open-Label Phase 1b Study of ORIC-101 in Combination With Enzalutamide in Patients With Metastatic Prostate Cancer Progressing on Enzalutamide
Status: Terminated, Estimated PCD: 2022-11-22
Product
ORIC-101
Product
MCLA-128
Clinical trial
Treatment Plan of the HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Status:
Clinical trial
A Real-World Comparison of Clinical Outcomes in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Initiated Enzalutamide vs. Abiraterone Acetate (Abiraterone) in Flatiron Electronic Health Record (EHR) Database
Status: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
Phase III Study of [18F]PSMA-1007 Positron Emission Tomography for the Detection of Prostate Cancer Lesions in Patients With Biochemical Recurrence After Previous Definitive Treatment for Localized Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-06-23
Product
BNT112
Clinical trial
First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 (BNT112) Monotherapy and in Combination With Cemiplimab in Patients With Prostate Cancer
Status: Terminated, Estimated PCD: 2024-01-23
Clinical trial
A Randomized, Open-label, Four-sequence, Four-period, Crossover, Single Dosing, Phase 1 Clinical Trial to Compare the Safety, Tolerability, and Pharmacokinetics of SOL-804 and Zytiga in Healthy Male Subjects
Status: Completed, Estimated PCD: 2023-10-28
Product
[18F]PSMA-1007
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2026-04-01
Clinical trial
A Phase 1 Study to Establish the Feasibility of Enolen (tm) for the Local Delivery of Enzalutamide in Patients With Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Product
Lutetium Lu 177 JH020002
Clinical trial
Phase 3 Study Investigating the Efficacy and Safety of TAVT-45 (Abiraterone Acetate) Granules for Oral Suspension (Novel Abiraterone Acetate Formulation) Relative to a Reference Abiraterone Acetate Formulation in Patients With mCSPC & mCRPC
Status: Completed, Estimated PCD: 2022-10-20
Product
Zytiga
Clinical trial
A Two Arm, Multi Centric, Randomised, Open Label, Parallel Study to Compare Pharmacodynamics of Subcutaneous Goserelin 10.8mg Injection (Sponsor) With ZOLADEX® 10.8mg Injection (AstraZeneca) in Patients With Advanced Prostate Cancer
Status: Recruiting, Estimated PCD: 2023-11-30
Product
Goserelin
Clinical trial
Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Preliminary Efficacy of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-05-01
Product
bicalutamide
Clinical trial
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Novel Hormonal Therapy (NHT) for Treating Patients With Metastatic Castration-Sensitive Prostate Cancer (mCSPC): An Analysis of National Veterans Affairs Health Care Network Data
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Product
EPI-7386
Clinical trial
A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 1/2 Study of Replicating Arenavirus-based Vector(s) Encoding Prostate Cancer-Associated Antigens in Participants With Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-09-01
Product
TAVT-45
Product
HB-302/HB-301
Product
Abivertinib
Clinical trial
A Phase 2 Study of AbiVERtinib in Combination With Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (Maverick Trial)
Status: , Estimated PCD: 2028-01-01
Clinical trial
A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen Therapy
Status: Terminated, Estimated PCD: 2023-02-27
Product
HPN424
Product
HPN424 Prime Step IV 36 ng/kg Target
Product
Olaparib
Clinical trial
A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment With One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
Status: Completed, Estimated PCD: 2022-03-14
Product
Prednisolone
Clinical trial
A Phase 1 Trial for Evaluation of Safety and 177Lu Radiation Dosimetry of CTT1403: A Peptidomimetic Inhibitor of Prostate Specific Membrane Antigen, in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Status: Completed, Estimated PCD: 2022-10-28
Product
CTT1057
Product
CTT1403
Clinical trial
A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN STUDY TO ASSESS THE EFFECT OF REPEATED SUBCUTANEOUS ADMINISTRATION OF PF-06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER AND ANOREXIA, FOLLOWED BY AN 18-WEEK OPEN-LABEL TREATMENT PERIOD
Status: Completed, Estimated PCD: 2022-04-14
Product
SOL-804-F
Product
PF-06946860
Product
PF-06946860 Placebo
Product
64Cu-SAR-BBN
Product
67Cu-SAR-BBN
Product
Cemiplimab
Clinical trial
A Phase I/IIa Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617
Status: Recruiting, Estimated PCD: 2026-05-01
Product
Gedatolisib
Product
Darolutamide
Clinical trial
Phase II, Open-label, Loading and Maintenance Dose Finding Study of GTx-758 in Men With Prostate Cancer
Status: Terminated, Estimated PCD: 2012-12-01
Clinical trial
A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Recruiting, Estimated PCD: 2025-11-01
Product
GTx-758
Clinical trial
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-06-01
Product
PC14586
Product
pembrolizumab
Clinical trial
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Status: Recruiting, Estimated PCD: 2026-03-17
Product
NUV-868
Clinical trial
Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2026-10-01
Clinical trial
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2019-02-19
Product
Naptumomab estafenatox
Product
Paclitaxel + Docetaxel + Carboplatin + Cisplatin
Product
FOLFOX
Product
Pegilodecakin
Product
gemcitabine/nab-paclitaxel
Product
Obinutuzumab
Clinical trial
ARI Treatment Use and Outcomes in Non-metastatic Prostate Cancer (nmPC) Patients in the US
Status: Completed, Estimated PCD: 2024-04-04
Product
Triptorelin
Product
Abemaciclib
Product
Relugolix
Product
CC-94676
Clinical trial
A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-06-30
Product
CC1083610
Product
CC1083611
Clinical trial
Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2026-07-07
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-07-30
Product
RO7656594
Clinical trial
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-02-15
Product
Keytruda
Clinical trial
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Status: Recruiting, Estimated PCD: 2028-05-31
Product
capivasertib
Clinical trial
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Status: Recruiting, Estimated PCD: 2026-10-23
Clinical trial
[Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer (ACCEL)
Status: Recruiting, Estimated PCD: 2027-08-01
Product
[Ac-225]-PSMA-62
Product
Ac-225-PSMA-62
Product
HPN424 Prime Step IV
Clinical trial
A Phase I Study of PCUR-101 in Combination With Androgen Directed Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Terminated, Estimated PCD: 2023-10-23
Product
Cyclophosphamide
Clinical trial
Multicenter, Open-label, Adaptive Design Phase I Trial With Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination With PSMA Peptide Target Module (TMpPSMA) for the Treatment of Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
Status: Terminated, Estimated PCD: 2024-03-28
Product
PCUR-101
Product
ARV-766
Clinical trial
A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-12-06
Product
ARV-766 + Abiraterone
Product
Fludarabine
Product
UniCAR02-T-pPSMA
Product
UniCAR02-T
Clinical trial
A Phase I/II Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
Status: , Estimated PCD: 2023-10-09
Clinical trial
MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status: Not yet recruiting, Estimated PCD: 2028-03-31
Clinical trial
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
Status: Recruiting, Estimated PCD: 2028-08-02
Product
Hydrocortisone
Product
Fludrocortisone
Product
Talazoparib
Product
SNS-101
Clinical trial
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-06-01
Product
AAA617
Clinical trial
An International Prospective Open-label, Multi-center, Randomized, Non-comparative Phase II Study of Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) Alone and Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) in Combination With Androgen Receptor Pathway Inhibitors in Patients With PSMA PET Scan Positive Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2028-12-21
Product
Piflufolastat F 18
Product
ARPI
Clinical trial
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-01-02
Clinical trial
A Single-arm, Open-label Phase 2 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy (ADT) in Chinese Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Status: Recruiting, Estimated PCD: 2024-10-26
Clinical trial
PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Status: Active (not recruiting), Estimated PCD: 2017-06-28
Product
Opevesostat
Clinical trial
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)
Status: Recruiting, Estimated PCD: 2030-12-02
Clinical trial
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
Quemliclustat
Product
NGM831 plus pembrolizumab
Product
NGM831 and NGM438 plus Pembrolizumab
Product
PT-112
Clinical trial
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of a Single Dose of Gallium [68Ga]-NYM032 Injection Prepared by Kit for the Preparation of the 68Ga-NYM032 Injection in Patients With Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-28
Product
Abiraterone/prednisone
Product
Fludrocortisone acetate
Clinical trial
A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status: Recruiting, Estimated PCD: 2026-01-12
Product
JNJ-69086420
Product
NGM831 + Pembrolizumab
Product
Ladiratuzumab vedotin
Clinical trial
A Multicentre Phase 2b Trial to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC), Suitable for Treatment With a Taxane
Status: Completed, Estimated PCD: 2021-11-29
Product
ModraDoc006/r
Product
SG
Product
LAE001
Product
Carboplatin
Product
T- Dxd
Clinical trial
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2026-12-15
Product
Camizestrant
Product
lorigerlimab
Clinical trial
A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-09-01
Product
AZD4635
Product
Oleclumab
Product
Durvalumab
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Status: Active (not recruiting), Estimated PCD: 2024-06-07
Clinical trial
A Phase 1 Safety, Tolerability, Biodistribution, Dosimetry and Efficacy Study of 177Lu-DOTA-TLX591 With Best Standard of Care in Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer
Status: Completed, Estimated PCD: 2023-09-30
Product
ARV-110
Clinical trial
TALAPRO-1: A PHASE 2, OPEN-LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE-BASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT (ENZALUTAMIDE AND/OR ABIRATERONE ACETATE/PREDNISONE)
Status: Completed, Estimated PCD: 2020-09-04
Clinical trial
A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination With Abiraterone in Patients With Metastatic Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Product
AAA517
Product
Androgen deprivation therapy (ADT)
Clinical trial
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status: Completed, Estimated PCD: 2021-01-27
Clinical trial
A Phase 1, Multicentre, Open-label, Nonrandomised, First-in-human Study of OVM-200 as a Therapeutic Vaccine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Ovarian Cancer, and Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Etrumadenant
Product
Zimberelimab
Product
Naptumomab estafenatox and Durvalumab
Product
Paclitaxel
Product
68Ga-NYM032
Product
Tazemetostat
Product
Gemcitabine/carboplatin
Product
Triptorelin embonate
Product
64Cu-DOTA-TLX592
Clinical trial
An Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of Triptorelin 6-month Formulation Administered Subcutaneously in Participants With Locally Advanced and/or Metastatic Prostate Cancer Previously Treated and Castrated With a GnRH Analogue
Status: Active (not recruiting), Estimated PCD: 2024-07-12
Clinical trial
A Phase 4 Open-Label Multicenter Study of PYLARIFY® PET/CT or PET/MRI in Men With Newly Diagnosed Favorable Intermediate Risk (FIR) Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Medication Adherence and Discontinuation Among Patients With Prostate Cancer Who Initiated Second Generation Androgen Receptor Inhibitors
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Prednisone or Prednisolone
Clinical trial
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Status: Terminated, Estimated PCD: 2023-11-28
Product
177Lu-DOTA-TLX591
Product
HPN424 2 Prime Step IV 300 ng/kg Target
Product
HB-302/HB-301 Alternating 2-Vector Therapy
Product
HS-10502
Clinical trial
A Phase 1 PK and Dose Escalation and Expansion Study of DST-2970 in Patients With Prostate Cancer With Rising PSA on Treatment With Abiraterone Acetate
Status: Active (not recruiting), Estimated PCD: 2023-03-31
Product
DST-2970
Clinical trial
TheraPb: Phase I/IIa Dose Escalation and Toxicity Study of [212Pb]Pb-ADVC001 in Metastatic Prostate Adenocarcinoma
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-04-01
Product
HRS-4357
Product
TALZENNA
Clinical trial
A PHASE 1, OPEN LABEL, CROSSOVER STUDY TO ESTABLISH BIOEQUIVALENCE BETWEEN THE PROPOSED SOFT GEL TALAZOPARIB CAPSULE FORMULATION AND THE CURRENT TALAZOPARIB COMMERCIAL FORMULATION AND TO ESTIMATE THE FOOD EFFECT ON PHARMACOKINETICS OF THE PROPOSED TALAZOPARIB SOFT GEL CAPSULE FORMULATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Status: Completed, Estimated PCD: 2022-02-04
Clinical trial
A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, Versus Enzalutamide Alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone
Status: Completed, Estimated PCD: 2019-10-18
Clinical trial
Impact of the Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone (GnRH) Agonist Therapy Initiated by the Urologist in the Routine Practice. Evaluation by the Patient and the Partner.
Status: Completed, Estimated PCD: 2017-11-01
Product
[212Pb]Pb-ADVC001
Product
177Lu-PSMA-R2
Clinical trial
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance, Safety & Timing of Postdose Imaging of ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Solid Tumors Undergoing Routine Surgery
Status: Completed, Estimated PCD: 2021-10-14
Clinical trial
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
Status: , Estimated PCD: 2024-12-01
Product
placebo
Product
valacyclovir
Clinical trial
A Phase 1b Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone or Apalutamide in mCRPC (ARES: Androgen Receptor Eradication Study)
Status: Terminated, Estimated PCD: 2022-09-30
Clinical trial
A Phase 1/2 Open-label, Multi-center, Dose-escalation Study of Safety, Tolerability, Pharmacokinetics, Dosimetry, and Response to Repeat Dosing of 177Lu-PSMA-R2 Radio-ligand Therapy in Patients With Prostate Specific Membrane Antigen (PSMA) Positive (68Ga-PSMA-R2) Progressive Metastatic Castration-resistant Prostate Cancer, Following Previous Systemic Treatment
Status: Terminated, Estimated PCD: 2021-05-26
Clinical trial
A Prospective, Open-Label, Single-Arm, Multi-center Study to Evaluate the Diagnostic Efficacy and Safety of 68Ga-PSMA-11 PET/CT or PET/MRI in Patients With Biochemical Recurrent Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
Status: Active (not recruiting), Estimated PCD: 2022-01-06
Product
OVM-200
Clinical trial
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO
Status: Recruiting, Estimated PCD: 2027-05-24
Product
Paclitaxel or Docetaxel and Carboplatin or Cisplatin
Product
Capecitabine
Product
Pazopanib
Clinical trial
A Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-12-26
Clinical trial
A Phase I, Single Centre, Open-label Study of TLX592 to Assess the Safety and Tolerability, Pharmacokinetics, Biodistribution and Radiation Dosimetry in Patients Diagnosed With Prostate Cancer
Status: Completed, Estimated PCD: 2023-12-30
Product
Lu-177-DGUL
Product
Ga-68-NGUL
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2020-03-16
Product
Ipatasertib
Product
Saruparib
Clinical trial
An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men With Newly Diagnosed Prostate Cancer (ASCERTAIN)
Status: Recruiting, Estimated PCD: 2025-02-25
Product
AZD5305
Product
ARV-110 with Abiraterone
Clinical trial
An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients With Prostate Cancer
Status: Completed, Estimated PCD: 2021-06-16
Product
ONM-100
Clinical trial
A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2026-05-01
Product
MRT-2359
Product
Oral MRT-2359
Product
BZ371A
Clinical trial
Phase 2 Clinical Trial to Evaluate Safety and Efficacy of BZ371A In A Gel Applied in Patients That Performed Radical Prostatectomy
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Oral Placebo
Product
Topical
Product
Gonadotropin-releasing Hormone agonist
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid Tumors
Status: Terminated, Estimated PCD: 2021-10-29
Product
[68Ga]P15-041
Clinical trial
A Randomized, Open-label, Parallel, Active-controlled Phase 1 Study to Compare Pharmacokinetics Pharmacodynamics and Safety of Goserelin Acetate Sustained-Release Microspheres for Injection (LY01022) With Zoladex® 10.8mg Following Single Administration in Patients With Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2023-12-01
Product
Bicalutamide
Clinical trial
A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer
Status: Completed, Estimated PCD: 2023-05-03
Clinical trial
A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CONTINUED ENZALUTAMIDE TREATMENT BEYOND PROGRESSION IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Status: Completed, Estimated PCD: 2016-11-15
Product
Goserelin Acetate
Product
Aglatimagene besadenovec
Product
[68Ga]P16-093
Clinical trial
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-01
Product
²¹²Pb-DOTAM-GRPR1
Clinical trial
A Multi-centre, Single-arm, Prospective Study to Assess Efficacy and Safety of Neoadjuvant Hormone Therapy Using Zoladex (Goserelin) and Casodex (Bicalutamide) in Patients With Advanced Prostate Cancer Undergoing Radical Prostatectomy.
Status: Terminated, Estimated PCD: 2022-11-09
Product
Cabozantinib
Clinical trial
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
A Phase 1 Open-Label Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Multi-center, Open-label, Single-arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy (ADT) in Treatment-naïve Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Status: Completed, Estimated PCD: 2023-10-23
Clinical trial
An Open-Label, Phase 1/1b, Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Status: Recruiting, Estimated PCD: 2023-05-01
Clinical trial
A Confirmatory, Prospective, Open-label, Single-arm, Reader-blinded Multi-centre Phase 3 Study to Assess the Diagnostic Accuracy of Ferumoxtran-10-enhanced Magnetic Resonance Imaging (MRI) and Unenhanced MRI in Reference to Histopathology in Newly-diagnosed Prostate Cancer (PCA) Patients, Scheduled for Radical Prostatectomy (RP) With Extended Pelvic Lymph Node Dissection (ePLND).
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Status: Completed, Estimated PCD: 2021-01-26
Clinical trial
A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)
Status: Completed, Estimated PCD: 2016-10-31
Product
Abiraterone acetate
Product
VERU-100
Product
Apitolisib
Clinical trial
A Phase Ib/II Study of Ipatasertib (GDC-0068) or Apitolisib (GDC-0980) With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Status: Completed, Estimated PCD: 2015-09-01
Product
18F-JK-PSMA-7
Clinical trial
Phase III Multicentre Prospective Comparative Study of Detection Rate of 18F-JK-PSMA-7 and of 18F-fluorocholine in Patients With Biochemical Recurrence of Prostate Cancer After Previous Treatment With Curative Intent
Status: Not yet recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Open-label, Multicenter, Phase 2b Study to Evaluate Physical Function, Including Balance and Daily Activity, in Participants With Castration-resistant Prostate Cancer Treated With Darolutamide or Enzalutamide
Status: Terminated, Estimated PCD: 2022-07-08
Clinical trial
An Open-Label, Multicenter, Dose Escalation And Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer
Status: Completed, Estimated PCD: 2023-05-24
Clinical trial
Phase 2 Multi-Center Randomized Controlled Feasibility Study of IS-002 in Subjects Undergoing Robotic-Assisted Radical Prostatectomy Using the da Vinci® Surgical System With Firefly® Fluorescence Imaging
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Terminated, Estimated PCD: 2016-07-01
Product
I-131-1095
Product
SHR7280
Clinical trial
An Open-label, Randomised, Multi-centre, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Six Different Dosing Regimens in Patients With Prostate Cancer Treated for 12 Months
Status: Completed, Estimated PCD: 2005-06-01
Clinical trial
An Open-Label, Multi-Center, Parallel and Sequential, Ascending Single Dose Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486 in Prostate Cancer Patients
Status: Completed, Estimated PCD: 2004-10-01
Clinical trial
AVM0703-EAP
Status:
Product
Proton pump inhibitor
Product
A166
Product
GEM3PSCA
Clinical trial
A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSCA Marker
Status: Terminated, Estimated PCD: 2023-06-28
Product
Paclitaxel + Carboplatin
Clinical trial
A Six Month, Multi-centre, Open-labelled, 1:1:1 Randomised, Parallel Group Study Investigating the Efficacy and Safety of Three Dose Regimens of FE 200486 in Prostate Cancer Patients
Status: Completed, Estimated PCD: 2002-05-01
Clinical trial
Phase I Study of CART-PSMA Cells in Patients With Advanced Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Degarelix
Product
CART-PSMA
Product
18F-PSMA-1007
Clinical trial
A Double Blind, Randomised, Dose Finding, Repeat Dose, Phase II, Multicentre Study of Alpharadin® for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases
Status: Completed, Estimated PCD: 2008-12-01
Product
MDPK67b
Clinical trial
Positron Emission Tomography Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA: A Multi-Centre, Blinded Review, Dose Ranging Phase I Study
Status: Completed, Estimated PCD: 2022-10-19
Product
BPX-601
Product
Rimiducid
Clinical trial
An Extension Long-Term Safety and Tolerability Trial of Degarelix, Following a 1-year Open-Label, Multi-Centre, Randomised, Parallel-group Trial in Which the Efficacy and Safety of Degarelix One-month Dosing Regimen Was Compared With Goserelin in Chinese Patients With Prostate Cancer Requiring Androgen Ablation Therapy
Status: Completed, Estimated PCD: 2017-08-01
Product
CC-90011
Clinical trial
Safety and Effect of Different Doses of TENDU Vaccine, a Therapeutic Peptide Conjugate Vaccine, in Patients With Relapse After Primary Radical Prostatectomy
Status: Active (not recruiting), Estimated PCD: 2023-08-31
Clinical trial
A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Previously Treated Advanced Solid Tumors
Status: , Estimated PCD: 2025-10-01
Clinical trial
A Phase 1/2 Open-label Trial of KVA12123 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-30
Product
KVA12123 Plus Pembrolizumab
Product
QLH12016
Clinical trial
Tolerance, Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2025-08-31
Clinical trial
A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2023-04-05
Product
etrumadenant
Product
zimberelimab
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)
Status: Withdrawn, Estimated PCD: 2026-05-31
Drug
Atezolizumab
Drug
UTD1
Clinical trial
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
Status: Completed, Estimated PCD: 2008-02-01
Product
GnRh (Leuprolide)
Product
Testosterone
Drug
Docetaxel
Clinical trial
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)
Status: Terminated, Estimated PCD: 2023-01-12
Clinical trial
Phase 1 Trial to Determine Safety and Feasibility in Treating Biochemical Recurrence Post-Prostatectomy With PSMA PET Guided External Beam Radiotherapy Followed by Consolidative Radioligand Therapy
Status: Recruiting, Estimated PCD: 2028-04-01
Product
Lutetium Lu 177 PSMA-10.1
Clinical trial
A Phase I Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist CORT-125134 (Relacorilant) for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
Status: Recruiting, Estimated PCD: 2026-01-10
Clinical trial
A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2021-08-31
Product
Niraparib
Product
Cetrelimab
Clinical trial
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-08-26
Product
LY4101174
Clinical trial
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Status: Active (not recruiting), Estimated PCD: 2022-02-10
Drug
177Lu-J591
Product
Ketoconazole
Product
111In-J591
Clinical trial
A Phase II Study of the Addition of Opaganib to Androgen Antagonists in Patients With Prostate Cancer Progression on Enzalutamide or Abiraterone
Status: Active (not recruiting), Estimated PCD: 2023-08-31
Product
Opaganib
Clinical trial
Effect of Non-steroidal Anti-inflammatory Drugs on Serum Prostate Specific Antigen Level
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Ibuprofen
Clinical trial
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)
Status: Completed, Estimated PCD: 2020-01-13
Clinical trial
Phase 2 Randomized Total Eradication of Metastatic Lesions Following Definitive Radiation to the Prostate in de Novo oligometaStatic Prostate Cancer (TERPS) Trial
Status: Recruiting, Estimated PCD: 2026-07-31
Product
Dato-DXd
Clinical trial
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2012-04-01
Clinical trial
A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen
Status: Completed, Estimated PCD: 2022-12-20
Product
Dutasteride
Product
Abiraterone + Prednisone
Clinical trial
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Tadalafil
Clinical trial
Phase 1 Clinical Trial Study to Evaluate Pharmacokinetics and Safety Profile of BZ371A in a Gel Formulation, Applied on Healthy Men and Women Genitals
Status: Completed, Estimated PCD: 2022-11-30
Clinical trial
A Phase I/II Clinical Study to Evaluate the Pharmacokinetics, Radiation Dosimetry, Safety and Preliminary Efficacy of HRS-4357 in Patients With PSMA Positive Advanced Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2024-09-30
Product
BI 836845
Clinical trial
A Randomized, Open-label and Parallel Phase I Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of Goserelin Acetate Sustained-Release Microspheres for Injection (LY01005) and ZOLADEX® Following Multiple Administration in Patients With Prostate Cancer
Status: Completed, Estimated PCD: 2021-09-15
Clinical trial
A Rollover Protocol For Patients Who Received Tremelimumab (CP-675,206 ) In Other Protocols
Status: Completed, Estimated PCD: 2023-10-27
Product
CP-675,206
Product
GEN1044
Product
HRS-9815
Product
NGM120
Clinical trial
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Status: Completed, Estimated PCD: 2023-02-16
Clinical trial
A Preliminary Evaluation of Uptake in Bone Metastases, Biodistribution and Excretion of the Novel Radiotracer [68Ga]P15-041 by PET/CT
Status: Completed, Estimated PCD: 2022-12-31
Product
ChAdOx1-PCAQ
Product
MVA-PCAQ
Product
Seribantumab
Clinical trial
Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics and Radiation Dosimetry of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer.
Status: Not yet recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Single-center, Open-label, Fixed-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of SHR3680 With Midazolam （CYP3A4 Substrates), S-Warfarin (CYP2C9 Substrates) and Omeprazole (CYP2C19 Substrates) in Prostate Cancer Patients
Status: Completed, Estimated PCD: 2022-01-26
Clinical trial
ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
Status: Terminated, Estimated PCD: 2016-09-01
Product
galeterone
Product
Selinexor
Product
LY01005
Product
ZOLADEX
Clinical trial
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Status: Terminated, Estimated PCD: 2023-01-19
Product
64Cu-PSMA I&T
Clinical trial
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10502 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Preliminary Investigation of Uptake in PSMA Expressing Cancer, Biodistribution and Excretion of the Novel Radio Tracer [68Ga]P16-093 by PET/CT
Status: Active (not recruiting), Estimated PCD: 2023-02-28
Product
NUV-422
Clinical trial
Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Status: Terminated, Estimated PCD: 2022-08-31
Product
Ferrotran
Product
acapatamab
Product
Rucaparib
Product
ORIC-944
Product
18F-Fluorocholine
Clinical trial
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer
Status: Completed, Estimated PCD: 2021-12-07
Product
BXCL701 plus Pembrolizumab
Clinical trial
Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype
Status: Active (not recruiting), Estimated PCD: 2023-10-01
Product
Lupron
Clinical trial
Phase II, Open Label, Dose Finding Study of the Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer Compared to a Luteinizing Hormone Releasing Hormone Agonist
Status: Terminated, Estimated PCD: 2012-12-01
Clinical trial
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager Acapatamab in Subjects With Metastatic Castration-resistant Prostate Cancer
Status: Completed, Estimated PCD: 2023-07-03
Product
Cytochrome P450 (CYP) Cocktail
Product
BXCL701
Product
Etanercept
Clinical trial
A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Are 18F-DCFPyL Prostate-specific Membrane Antigen (PSMA)-Avid, Chemotherapy-naive, and Progressed on Abiraterone
Status: Active (not recruiting), Estimated PCD: 2023-09-21
Product
degarelix
Clinical trial
Explore the Relationship Between Single Nucleotide Polymorphisms and Abiraterone Response and Toxicity in Patients With Prostate Cancer.
Status: Active (not recruiting), Estimated PCD: 2024-05-18
Product
AVM0703
Clinical trial
A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies
Status: Completed, Estimated PCD: 2022-01-12
Clinical trial
Open Label Study of the Effect of GTx-758 on Serum PSA and Free Testosterone Levels in Men With Castration Resistant Prostate Cancer and Maintained on Androgen Deprivation Therapy
Status: Terminated, Estimated PCD: 2012-12-01
Clinical trial
Efficacy, Safety, and Pharmaco-kinetics of Leuprolide Acetate for Injection 3.75mg (Depot) (Leuprorelin) Administered in Subjects With Advanced Adenocarcinoma of Prostate: A Randomized, Active Controlled, Comparative, Open-Label, Multi-Center, Phase 3 Study
Status: Completed, Estimated PCD: 2022-09-29
Product
Galeterone
Product
Leuprolide Acetate
Product
BR55
Product
Autologous T cells & Cyclophosphamide
Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Product
HRS-5041
Clinical trial
Open-label Phase Ib Study of Preoperative Treatment With the KLK Inhibitor MDPK67b in Patients With Untreated Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-06-30
Product
KVA12123
Product
Systemic Treatment
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Product
PF-06755992
Clinical trial
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN (VBIR) FOR PROSTATE CANCER (PF-06753512)
Status: Terminated, Estimated PCD: 2021-02-23
Product
PF-06801591
Clinical trial
A Real-World Comparison of Clinical Outcomes in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Initiated Enzalutamide vs. Abiraterone Acetate (Abiraterone) in the 100% Medicare Fee-For-Service (FFS) Data (2009-2020)
Status: Completed, Estimated PCD: 2023-06-30
Product
ARX517
Clinical trial
A Phase 1/2, Multicenter, Open-Label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 as Monotherapy and in Combination Regimens, With Randomized Comparison to Investigator's Choice of Treatment, in Subjects With Metastatic Castration-resistant Prostate Cancer Who Are Resistant or Refractory to Prior Standard Therapies
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-01
Product
MCS®
Clinical trial
The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer
Status: Recruiting, Estimated PCD: 2028-02-01
Clinical trial
Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia
Status: Active (not recruiting), Estimated PCD: 2023-09-01
Drug
GnRH agonist
Clinical trial
Neoadjuvant [177Lu]Lu-PSMAI&T Radioligand Therapy (PSMA-RLT) for Patients With Oligometastatic Prostate Cancer Diagnosed Using [68Ga]Ga-PSMA-11 PET Imaging Followed by Radical Prostatectomy: A Prospective Phase II Pilot Study
Status: Recruiting, Estimated PCD: 2027-01-01
Product
Lu-PSMA I&T
Clinical trial
Evaluating the Efficacy and Safety of Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-12-31
Product
ADT+second-generation antiandrogens
Clinical trial
Tracer-Based Image Guided Surgery for Recurrent Prostate Cancer: A Prospective Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-11-01
Drug
ADT
Clinical trial
A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-04-30
Product
ZEN-3694
Product
Systemic Therapy
Clinical trial
A Phase 2 Randomized Trial of Neoadjuvant Enoblituzumab Versus Standard of Care in Men With High-Risk Localized Prostate Cancer: The Help Elucidate & Attack Longitudinally (HEAT) Prostate Cancer Randomized Study
Status: Recruiting, Estimated PCD: 2029-03-01
Drug
Enoblituzumab
Clinical trial
Phase II Study of Talazoparib With Androgen Deprivation Therapy and Abiraterone in Castration Sensitive Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-08-23
Drug
Abiraterone Acetate
Clinical trial
177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High- and Very High-risk Prostate Cancer After Radical Treatment Using Locoregional Teleradiotherapy and Hormone Therapy
Status: Not yet recruiting, Estimated PCD: 2030-11-01
Product
Lutetium vipivotide tetraxetan
Clinical trial
Immunogenic Priming With PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer: A Phase 1b Study of 177Lu-PSMA-617 in Combination With Pembrolizumab
Status: Active (not recruiting), Estimated PCD: 2024-01-10
Product
Lutetium Lu 177-PSMA-617
Clinical trial
Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Vinorelbine
Product
Vismodegib
Clinical trial
Phase 2 Study of 18F-DCFPyL Positron Emission Tomography (PET) in Men With Intermediate or High Risk Biochemically Recurrent Prostate Cancer
Status: Terminated, Estimated PCD: 2022-12-31
Clinical trial
A Phase III, Double-blind, Placebo-controlled, Randomised Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
Status: Recruiting, Estimated PCD: 2026-10-01
Product
Aspirin
Product
18F-DCFPyL
Clinical trial
Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Product
Methylphenidate
Clinical trial
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)：a Prospective, Single-arm, Phase II Clinical Study
Status: Recruiting, Estimated PCD: 2025-07-30
Drug
Anlotinib
Clinical trial
Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2017-07-10
Drug
LHRH agonist
Clinical trial
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity, PSA Decline and Genetic Variation in Proteins Involved in Androgen Metabolism in Metastatic Hormone Naive Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)
Status: Active (not recruiting), Estimated PCD: 2024-03-15
Product
Testosterone Cypionate
Clinical trial
Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression
Status: Active (not recruiting), Estimated PCD: 2016-12-31
Product
Drug
Clinical trial
A Phase II Trial of Androgen Deprivation, Docetaxel and Enzalutamide in Patients With Metastatic Hormone Sensitive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2022-09-01
Product
ADT+Docetaxel+Enzalutamide
Clinical trial
Re-Treatment With 177Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer: A Prospective Phase 2 Trial (RE-LuPSMA STUDY)
Status: Not yet recruiting, Estimated PCD: 2026-01-27
Product
Lutetium Lu 177 Vipivotide Tetraxetan
Clinical trial
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-3475) for Solid Tumors
Status: Recruiting, Estimated PCD: 2025-11-21
Product
Recombinant EphB4-HSA Fusion Protein
Clinical trial
A Phase Ib Study of Extending Relugolix Dosing Intervals Through Addition of the CYP3A4 and Pg-P Inhibitor Itraconazole or Ritonavir in Prostate Cancer Patients
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Itraconazole
Clinical trial
Square Wave Testosterone Therapy in Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
Transdermal Testosterone
Clinical trial
Overcoming Drug Resistance in Metastatic Castration-resistant Prostate Cancer With Novel Combination of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide: a Randomized Multi-site Phase II Study
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
LY2157299
Clinical trial
Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer: A Randomized Feasibility Study
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Product
Hormone therapy
Clinical trial
Phase II Trial of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (HP) Plus Enzalutamide for the Treatment of Selected Patients With Metastatic Castration-Resistant Prostate Cancer (TraPPer)
Status: Recruiting, Estimated PCD: 2025-10-01
Product
Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Clinical trial
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Status: Recruiting, Estimated PCD: 2025-01-31
Product
Avelumab
Product
XmAb®22841
Clinical trial
A Phase-2, Open-Label Study of Oral Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Terminated, Estimated PCD: 2016-04-01
Product
PNT2258
Clinical trial
A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma
Status: Active (not recruiting), Estimated PCD: 2023-05-01
Product
GZ17-6.02
Clinical trial
A Multi-Center, Open-Label, Randomized Phase 2 Study of Copper Cu 64 PSMA I&T Injection in Patients With Histologically Proven Metastatic Prostate Cancer
Status: Completed, Estimated PCD: 2023-05-17
Product
Botensilimab
Product
Balstilimab
Product
IS-002
Clinical trial
Exploratory Clinical Trial Using BR55 Targeted Ultrasound Contrast Agent in the Detection of Prostate Cancer by Molecular Imaging of VEGFR2
Status: Completed, Estimated PCD: 2012-12-01
Product
QBS10072S
Clinical trial
A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma
Status: Completed, Estimated PCD: 2022-09-21
Clinical trial
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Valacyclovir
Product
Aglatimagene Besadenovec + Valacyclovir
Clinical trial
A Phase III, Open-Label, Multi-center Clinical Study to Assess the Diagnostic Performance and Safety of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-11-01
Product
Florastamin
Clinical trial
A Phase 1, Open-label, Functional Imaging Study to Assess Whether CC-90011 Reverses the Castration Resistance Due to Lineage Switch in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Have Failed Enzalutamide as Last Prior Therapy, Followed by a Dose Finding Study of CC-90011 Combined With Abiraterone and Prednisone
Status: Completed, Estimated PCD: 2023-05-26
Clinical trial
Multicenter Evaluation of Diagnostic Performance of [18F]FPSMA-1007 PET/CT in Patients With Suspected Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer
Status: Recruiting, Estimated PCD: 2033-07-20
Product
TENDU
Product
PF-06755990
Product
Tremelimumab
Product
PF-06753512
Product
SRF617
Product
TH1902
Clinical trial
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS® in Prostate Cancer Prevention
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Evaluation of Patients With Low-Risk and Intermediate-Risk Prostate Cancer Scheduled for High-Dose Rate Brachytherapy Using 68-Ga-RM2 PET, 68Ga-PSMA-11 PET and Multi Parametric MRI
Status: Terminated, Estimated PCD: 2022-11-22
Product
68-Ga RM2
Product
68-Ga PSMA11
Clinical trial
The Utility of PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men With High GC Decipher® Test Scores: A Sub-aim of the VANDAAM Study (MCC #18523)
Status: Recruiting, Estimated PCD: 2029-05-01
Product
F-DCFPyL
Clinical trial
A Phase II Trial of PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer - The OCEAN Trial
Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Phase II Randomized Study of Sipuleucel-T With or Without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer With PSA Progression While on NHA and LHRH Analog
Status: Recruiting, Estimated PCD: 2025-10-01
Product
Sipuleucel-T
Clinical trial
Establishing a Neo-Adjuvant Platform for Developing Targeted Agents: Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Drug
androgen deprivation therapy
Clinical trial
Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: a Multi-center Randomized Controlled Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Product
ADT combined with Abiraterone
Clinical trial
Ultrasound Guided Inguinal Indocyanine Green Injection to Identify and Pre-emptively Seal Lymphatic Leaks
Status: Not yet recruiting, Estimated PCD: 2026-02-01
Product
ICG
Clinical trial
Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen
Status: , Estimated PCD: 2024-05-29
Drug
Aspirin
Product
Recombinant Interferon Alfa-2b
Drug
Rintatolimod
Product
Androgen Receptor Signaling Inhibitor
Clinical trial
Enzalutamide and Metformin Combination Therapy to Overcome Autophagy Resistance in Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
Adavosertib
Product
Savolitinib
Product
CFI-400945
Product
Durvalumab and Tremelimumab
Product
Relacorilant
Clinical trial
PLATPARP: A Phase II Single-Arm Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Drug
AN0025
Product
Cobimetinib
Clinical trial
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-04-30
Drug
Androgen deprivation therapy
Clinical trial
A Phase 1 Study of [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
Status: Terminated, Estimated PCD: 2023-04-21
Product
[18F]FLOR (FC303)
Drug
Entrectinib
Product
Eribulin
Clinical trial
A Pilot Study of Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
Status: Terminated, Estimated PCD: 2021-06-16
Drug
cyclophosphamide
Drug
testosterone cypionate
Clinical trial
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status: Active (not recruiting), Estimated PCD: 2018-03-19
Drug
Abiraterone acetate
Drug
R-CHOP
Clinical trial
Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
BMS-986253
Clinical trial
A First-in-Human, Phase I/II PET Imaging Study of 64Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Copper-64 labeled Granzyme B
Clinical trial
A Randomized, Multicenter, Prospective Phase II Trial to Assess the Effect of Short- Versus Long-term Adjuvant ADT With High Dose Salvage Radiotherapy on Distant Metastasis Free Survival in Patients With Biochemical Relapse After Radical Prostatectomy
Status: Recruiting, Estimated PCD: 2026-02-01
Product
Triptoreline
Clinical trial
A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2022-04-29
Product
Palbociclib
Product
Ritonavir
Clinical trial
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Status: Active (not recruiting), Estimated PCD: 2026-06-30
Product
Denosumab
Clinical trial
LCCC 1917: Dose Escalation of Low and Intermediate Risk Localized Prostate Cancer Using 68Ga-HBED-CC PSMA-PET/MRI and Stereotactic Body Radiotherapy
Status: Withdrawn, Estimated PCD: 2024-02-07
Product
68Ga-HBED-CC-PSMA
Clinical trial
NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
Status: Recruiting, Estimated PCD: 2025-06-30
Product
177Lu rhPSMA-10.1
Product
177Lu rhPSMA-10.1 plus Degarelix
Clinical trial
Relationship Between Image-derived Features of Intraoperative ICG Visualization of Periprostatic Vasculature and NVBs During RARP and Functional Outcomes
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Pilot Study of PSMA-TRT Re-treatment Utilizing 225Ac-J591
Status: Recruiting, Estimated PCD: 2025-12-31
Product
225Ac-J591
Clinical trial
Phase IB Trial of Relugolix and Enzalutamide as Neoadjuvant/ Adjuvant to Local-regional Treatment in Patients With High-risk Locally Advanced Prostate CAncer (RENAPCA)
Status: Not yet recruiting, Estimated PCD: 2029-04-01
Product
Relugolix + Enzalutamide
Clinical trial
Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain
Status: Completed, Estimated PCD: 2022-09-02
Product
Nitrous Oxide
Clinical trial
Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate
Status: Terminated, Estimated PCD: 2020-11-01
Drug
Metformin
Clinical trial
A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2026-07-13
Product
Tamsulosin
Product
Peposertib
Clinical trial
The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase 2 Clinical Trial of Pembrolizumab in Combination With Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-11-01
Drug
Tiragolumab
Product
Pertuzumab
Clinical trial
Randomized Phase II Study of Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide Progression
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Product
Docetaxel + Prednisone
Clinical trial
A Phase 2 Study of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer
Status: Completed, Estimated PCD: 2023-04-12
Product
Ibrutinib
Clinical trial
INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-03-01
Product
GnRH Agonist
Clinical trial
A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Berzosertib
Clinical trial
A Phase 2 Trial of Radium Ra 223 Dichloride in Combination With Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients With Oligometastatic Castration Sensitive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-04-09
Product
Perflutren Lipid Microspheres
Clinical trial
A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
4-2023-1306
Status: Recruiting, Estimated PCD: 2026-11-01
Product
Ifosfamide/mesna
Clinical trial
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Status: Recruiting, Estimated PCD: 2024-12-01
Drug
Tivozanib
Clinical trial
A Phase II Trial of Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy
Status: Completed, Estimated PCD: 2024-04-29
Product
PROSTVAC-V/F
Clinical trial
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Product
PCR/PCR/LDR Strategy
Clinical trial
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Status: , Estimated PCD: 2029-12-31
Drug
18F-FDG
Product
PSMA-11
Clinical trial
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
Status: Recruiting, Estimated PCD: 2024-03-01
Product
18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent
Clinical trial
A Phase I/II Basket Trial Evaluating a Combination of Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumour
Status: Active (not recruiting), Estimated PCD: 2022-04-01
Product
Durvalumab + Tremelimumab + Vinorelbine
Clinical trial
Pre-Surgical EPS Biomarkers as Predictors of Biochemical Recurrence
Status: Active (not recruiting), Estimated PCD: 2016-07-13
Product
DNA methylation analysis
Product
RNA analysis
Product
Gene Expression Analysis
Product
Polymerase Chain Reaction
Clinical trial
Phase II Trial of Targeted Radiation With no Castration for Mcrpc
Status: Recruiting, Estimated PCD: 2027-11-29
Drug
Pluvicto
Product
Topical Testosterone
Clinical trial
Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer: ENZARAD
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Conventional NSAA
Product
LHRHA
Product
Metformin
Clinical trial
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-06-19
Clinical trial
Effects of a Genistein Concentrated Polysaccharide (GCP) on Patients With a Diagnosis of Prostate Cancer on Active Surveillance.
Status: Completed, Estimated PCD: 2005-12-01
Product
GCP - Genistein Combined Polysaccharide
Clinical trial
Autonomic and Renal Contributions to Hypertension With Androgen Deprivation Therapy
Status: Recruiting, Estimated PCD: 2028-03-31
Product
Gonadotropin-Releasing Hormone Agonist
Product
Androgen receptor inhibitor
Clinical trial
A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2019-10-16
Product
Fulvestrant
Clinical trial
A Randomized Phase III Trial Investigating Platinum and Taxane Chemotherapy in Metastatic Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
Status: Not yet recruiting, Estimated PCD: 2029-09-30
Clinical trial
Phase IB/II Study of Enzalutamide With Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression
Status: Completed, Estimated PCD: 2022-12-06
Product
Ribociclib
Clinical trial
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors; a Phase 3 Pragmatic Randomized Trial.
Status: Not yet recruiting, Estimated PCD: 2029-09-15
Product
iMAB
Product
cMAB
Clinical trial
The Role of Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients Treated With Radical Prostatectomy and Extended Pelvic Lymph Node Dissection
Status: Recruiting, Estimated PCD: 2024-11-15
Product
99m-TC-PSMA-I&S
Clinical trial
A Phase 1b Study of Adaptive Androgen Deprivation Therapy for State IV Castration Sensitive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2022-06-22
Product
Adaptive Androgen Deprivation Therapy
Clinical trial
A Phase II Study of Fluorine-18 (18F)-Labeled PSMA-1007 in Patients With Known or Suspected Metastatic Prostatic Carcinoma
Status: Recruiting, Estimated PCD: 2025-12-01
Product
[18]F-PSMA-1007
Clinical trial
A Phase 2 Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) in Patients With Prostate Cancer on Active Surveillance
Status: Recruiting, Estimated PCD: 2025-03-31
Product
Hyperpolarized Carbon C 13 Pyruvate
Clinical trial
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
Status: Recruiting, Estimated PCD: 2024-05-28
Product
rhPSMA-7.3
Clinical trial
A Pilot Study of Cisplatin in Castration Resistant Prostate Cancer That is Becoming Refractory to Enzalutamide
Status: Completed, Estimated PCD: 2023-07-31
Drug
Cisplatin
Clinical trial
An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Phase I, Open-label, Single-center Proof of Concept Study Designed to Test the Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in Combination With CDX-301 in Subjects With a History of Prostate Cancer, in the Adjuvant Setting
Status: Recruiting, Estimated PCD: 2027-01-01
Product
PGV-001
Drug
Poly-ICLC
Drug
CDX-301
Clinical trial
Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
FASN Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer Salvaging Taxane Failure
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Omeprazole
Clinical trial
Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)
Status: Recruiting, Estimated PCD: 2024-06-26
Clinical trial
A Cancer Research UK Phase I/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2026-09-01
Product
HTL0039732
Clinical trial
A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccine in Previously Vaccinated Men on NCI 09-C-0139.
Status: Completed, Estimated PCD: 2022-03-25
Product
Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine
Clinical trial
A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Status: Recruiting, Estimated PCD: 2027-03-05
Drug
PF-07220060
Product
Letrozole
Clinical trial
Repeat Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Asymptomatic Patients With Metastatic Castration-Resistant Prostate Cancer: The APEX (Androgen and Polyamine Elimination Alternating With Xtandi) Trial
Status: Recruiting, Estimated PCD: 2026-01-04
Product
DFMO
Product
Luteinizing hormone-releasing hormone analogue
Clinical trial
A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-03-14
Clinical trial
Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate (PORT-MAP)
Status: Terminated, Estimated PCD: 2023-09-22
Product
Osanetant
Drug
Abraxane
Clinical trial
Randomized Trial of Adjuvant Curcumin After Prostatectomy
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Curcumin
Drug
placebo
Clinical trial
A Phase 2 Risk Adapted Parallel Randomized Trial of MRI-Guided Lattice Stereotactic Focal Radiotherapy of the Prostate With or Without Ultra-Short Term Androgen Deprivation Therapy-The Miami UAdapt Trial
Status: Not yet recruiting, Estimated PCD: 2027-09-01
Product
Ultra-Short-Term Androgen Deprivation Therapy with Relugolix
Clinical trial
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
Status: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in Patients With Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Feasibility Study of Oral Hormonal Therapy and Radiation for Non-metastatic, Intermediate or High Risk Prostate Cancer in Men 70 and Older or With Medical Comorbidities
Status: Active (not recruiting), Estimated PCD: 2020-05-01
Drug
Dutasteride
Drug
Finasteride
Clinical trial
Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)
Status: Active (not recruiting), Estimated PCD: 2023-11-08
Clinical trial
GU-01: Glycyrrhizin in Prostate Cancer: A Window-of-Opportunity Trial
Status: Recruiting, Estimated PCD: 2026-03-01
Product
Glycyrrhizin
Clinical trial
EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T: Phase I/II Study
Status: Active (not recruiting), Estimated PCD: 2024-08-03
Product
Tb PSMA I&T
Clinical trial
An Evolutionary Double Bind Phase II Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer Eligible for Prostatectomy
Status: Withdrawn, Estimated PCD: 2025-01-01
Product
Neoadjuvant treatment
Clinical trial
68Ga-PSMA-11 Positron Emission Tomography / Computed Tomography (PET/CT) for Assessment of High Risk or Recurrent Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-08-01
Drug
68Ga-PSMA-11
Clinical trial
SAXON-PC: A Phase II Randomized Trial of Stereotactic Body Radiation Therapy (SBRT) And Radium (Ra-223) Dichloride for Oligorecurrent, Non-castrate Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-11-12
Product
Radium dichloride
Clinical trial
An Open-label, Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With and Without SRC or MEK Inhibition on the Development of EMT in Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Drug
enzalutamide
Drug
trametinib
Drug
dasatinib
Clinical trial
A Phase I Pilot Study of Samarium-153 Combined With Neoadjuvant Hormonal Therapy and Radiation Therapy in Men With Locally Advanced Prostate Cancer
Status: Completed, Estimated PCD: 2009-02-01
Product
Samarium-153
Product
Total Androgen Suppression (TAS) with Bicalutamide
Product
Total androgen suppression (TAS) with Goserelin Acetate
Clinical trial
A Phase II Study of Ipilimumab PLUS Androgen Depravation Therapy in Castrate Sensitive Prostate Carcinoma
Status: Terminated, Estimated PCD: 2017-04-07
Clinical trial
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
Status: Completed, Estimated PCD: 2023-12-07
Clinical trial
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2019-08-12
Product
Sunitinib
Product
Dasatinib
Clinical trial
A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Product
LHRH Agonist
Clinical trial
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Status: Completed, Estimated PCD: 2022-03-08
Product
68Ga RM2
Clinical trial
Prostate Cancer Diagnosis by Multiparametric Ultrasound (Clinical)
Status: Not yet recruiting, Estimated PCD: 2026-08-01
Product
Perflutren lipid microsphere
Clinical trial
Longitudinal Evaluation of Adding Docetaxel to ADT and Novel Hormone Treatment for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer in Order to Assess Relative Effectiveness: the Case of "Triple" Versus "Double" Therapy
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy: A Randomized Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2028-12-01
Clinical trial
4-aminopyridine Treatment for Nerve Injury Resulting From Radical Retro-Pubic Prostatectomy
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Product
4-Aminopyridine
Clinical trial
A Phase I/II Study of M9241 With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and M9241 With Docetaxel in Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Product
M9241
Clinical trial
A Phase 2 Study of Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-05-31
Drug
177Lu-PSMA-617
Clinical trial
Effectiveness of RaproCell in Alleviating the Side Effects of Chemotherapeutic Agents, Without Adversely Impacting the Overall Success of the Agents on Cancer Cells.
Status: Completed, Estimated PCD: 2022-10-18
Product
Chemotherapeutic agent A
Clinical trial
PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
11C-Choline
Clinical trial
A Randomized Open Label Phase II Trial of FDG-PET-Guided Metastasis Directed Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer: PRTY Trial: PET- Guided Radiotherapy Consolidation
Status: Recruiting, Estimated PCD: 2027-02-18
Product
Antiandrogen Therapy
Product
Cytotoxic Chemotherapy
Clinical trial
Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Status: Active (not recruiting), Estimated PCD: 2023-05-03
Clinical trial
Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment
Status: Active (not recruiting), Estimated PCD: 2019-10-01
Clinical trial
The Safety and Efficacy of 68Ga-HBED-CC-PSMA PET/CT in Prostate Cancer
Status: Completed, Estimated PCD: 2023-07-01
Clinical trial
A Randomized Phase I/II Study of Neoadjuvant Treatment With 177-Lutetium- PSMA-617 With or Without Ipilimumab in Subjects With Very High-risk Prostate Cancer Who Are Candidates for Radical Prostatectomy (NEPI Trial)
Status: Not yet recruiting, Estimated PCD: 2027-03-01
Clinical trial
Transperineal Interstitial Permanent Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Active (not recruiting), Estimated PCD: 2026-09-30
Product
Brachytherapy
Clinical trial
Targeted Drug Intervention in Men at Risk of Progression on Active Surveillance for Early Prostate Cancer: A Randomised Trial - Therapeutics in Active Prostate Cancer Surveillance (TAPS02).
Status: Recruiting, Estimated PCD: 2031-04-01
Clinical trial
Prostate Specific Membrane Antigen (PSMA) or Fluciclovine (FACBC) PET/CT Site-Directed Therapy of OLigometASTatic Prostate Cancer (P-Flu-BLAST-PC): A Multicenter Study
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Trastuzumab Emtansine
Clinical trial
A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Study to Assess the Diagnostic Performance of 18F-Thretide PET/CT in Men With Prostate Cancer
Status: Completed, Estimated PCD: 2023-03-31
Product
18F-Thretide
Clinical trial
The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Statin
Product
ACE inhibitor
Clinical trial
A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2021-11-22
Clinical trial
Phase 2 Study of Extreme Hypofractionation Including Pelvic Nodes for High Risk Prostate Cancer Using MgRT (MRI Guided Radiation Therapy)
Status: , Estimated PCD: 2025-12-31
Product
EP0057
Clinical trial
Utility of Exosomal microRNAs to Predict Response to Androgen Deprivation Therapy in Prostate Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2021-05-11
Product
ADT Standard of Care
Clinical trial
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-05-15
Clinical trial
The Effect of a Soy Bread Diet Intervention on Immune Function in Men With Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2022-03-09
Product
Dietary Intervention
Clinical trial
Phase II Trial of Short Course Androgen Deprivation, Hypofractionated Pelvic Radiation and a Brachytherapy Boost for NCCN High-Risk Prostate Cancer With Low-Intermediate Risk Decipher Genomic Score
Status: Active (not recruiting), Estimated PCD: 2025-10-19
Product
Androgen deprivation therapy
Clinical trial
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2021-05-18
Product
TAK-700
Clinical trial
A Phase 2, Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Metastatic Prostate Cancer Patients Evaluating a Predetermined Biomarker Signature
Status: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
Prostate Cancer Risk Assessment Using Genetic Markers in General Practice
Status: Active (not recruiting), Estimated PCD: 2025-10-30
Product
Genetic risk assessment
Clinical trial
SPECT Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413 ([99mTc]Tc- BQ0413) in Prostate Cancer Patients
Status: , Estimated PCD: 2024-05-31
Product
BQ0413
Clinical trial
Quantification of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Metastasis of Breast Carcinoma Patients and Assessment of Repeatability (VUBAR) - Pilot Study
Status: Recruiting, Estimated PCD: 2024-11-01
Product
68GaNOTA-Anti-HER2
Clinical trial
Phase 2 Study of Bright White Light During Treatment With ADT Combination Therapy in Men With Advanced Prostate Cancer to PreServe PHysIcal and MeNtal HEalth (SHINE)
Status: Recruiting, Estimated PCD: 2027-12-01
Product
Combination Drug Therapy
Clinical trial
A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer
Status: Terminated, Estimated PCD: 2011-03-01
Product
2-deoxyglucose
Clinical trial
An Open-Label Multi-Center Phase II Study of Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
Status: Recruiting, Estimated PCD: 2025-02-28
Drug
Tocilizumab
Clinical trial
A Phase 2 Study of 68Ga-PSMA-11 PET in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2022-07-01
Product
PROSTVAC-V
Product
PROSTVAC-F
Clinical trial
PSMA PET Imaging of Recurrent Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Ga-HBED-iPSMA PET
Clinical trial
PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study
Status: Completed, Estimated PCD: 2022-02-23
Product
PSMA-PET/MRI or PET/CT
Clinical trial
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Active (not recruiting), Estimated PCD: 2013-12-01
Clinical trial
Phase IIIb Randomized Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer. A Joint Study of the EORTC ROG and GUCG
Status: Active (not recruiting), Estimated PCD: 2023-11-06
Product
GnRH agonist
Drug
FOLFOXIRI
Product
Cediranib
Clinical trial
A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
STM-416p
Clinical trial
Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Drug
177Lu-PSMA-617
Clinical trial
Multimodal PET/MRI Machine Learning Approaches for Characterization of Solid Tumors
Status: Recruiting, Estimated PCD: 2024-08-31
Product
[18F]DCFPyL
Clinical trial
68Ga-NeoBOMB1 and 68Ga-PSMA R2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer
Status: Completed, Estimated PCD: 2022-02-11
Product
Gallium Ga 68 DOTA-NeoBOMB1
Clinical trial
Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve-Sparing Radical Prostatectomy Versus Standard of Care
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Stravix
Clinical trial
Comparison of Viscoelastic Test-guided and Preemptive Tranexamic Acid Administration Strategies in High-risk Non-cardiac Surgery
Status: Recruiting, Estimated PCD: 2024-12-01
Product
TXA
Drug
degarelix
Clinical trial
Cross-Over Trial to Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Étude Pilote randomisée de Phase IIB, contrôlée Par placébo, évaluant l'Effet thérapeutique d'Une supplémentation en Omega-3 (Principalement EPA) Chez Des Patients en récidive Biochimique ou en Progression du Cancer de la Prostate.
Status: Recruiting, Estimated PCD: 2024-12-01
Product
MAG-EPA
Clinical trial
Phase III Study of Image Guided Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate
Status: , Estimated PCD: 2025-12-01
Product
Androgen Suppression
Clinical trial
Phase II Randomized Study Of Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide For Intermediate-High Risk Prostate Cancer Undergoing Prostatectomy
Status: Active (not recruiting), Estimated PCD: 2023-05-01
Clinical trial
Open Label Phase II Trial of Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) and Known Amplifications or Activating Mutations in Gene Targets of Cabozantinib Who Have Received Prior Anti-Androgen Therapy
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
High Precision Stereotactic Radiotherapy to the Whole Prostate With Focal Boost and Varying Hormonal Therapy (HEATWAVE)
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Phase 2 Combination Trial of Tivozanib and Enzalutamide in Men With Advanced Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
IIT2021-09-Posadas-NA-TAZ: A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer
Status: Withdrawn, Estimated PCD: 2025-12-01
Product
Tazverik
Clinical trial
Use of β-hydroxy-β-methylbutyrate to Counteract Loss of Muscle Mass and Strength in Older Men With Prostate Cancer Started on Androgen Deprivation Therapy
Status: Completed, Estimated PCD: 2018-07-01
Product
Standard of care ADT
Clinical trial
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Product
Fluzoparib
Clinical trial
The BARCODE 1 Study: The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Product
Genetic SNP profiling
Clinical trial
A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2022-09-28
Product
PROSTVAC
Clinical trial
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-06-01
Product
Lutetium-177 PSMA-I&T
Drug
Radium-223
Clinical trial
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)
Status: Recruiting, Estimated PCD: 2030-08-15
Drug
AZD5305
Clinical trial
A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
Prospective Biomarker Analysis of Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Undergoing Sequential Treatment With Docetaxel and Enzalutamide
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
Phase II Study Evaluating the Effects of Single Site Intratumoral Injections of Anti-CD40 Agonist Antibody (2141-V11) Given as Monotherapy Prior to Radical Prostatectomy to Men With Intermediate Risk Disease and in Combination With Androgen Deprivation Therapy for Those With High Risk Localized and Low Volume Metastatic Disease
Status: Recruiting, Estimated PCD: 2029-03-28
Product
2141-V11
Clinical trial
A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
Trastuzumab
Clinical trial
A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Hyperpolarized 13C-Pyruvate
Product
Hyperpolarized 13C,15N2-urea
Clinical trial
Phase II Clinical and Translational Study of Neoadjuvant Pembrolizumab Before Radical Prostatectomy in Non-metastatic Gleason ≥8 Prostate Cancer Patients Positive by 18FDG-PET Scanning ( PICT-01)
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Pilot Trial to Explore the Link Between Immunological Changes, Efficacy, Safety, and Tolerability of Durvalumab (MEDI4736) Plus Tremelimumab in Chemotherapy-Naïve Men With Metastatic Castration-Resistant Prostate Cancer (CRPC)
Status: Completed, Estimated PCD: 2021-04-13
Clinical trial
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Status: Active (not recruiting), Estimated PCD: 2020-09-07
Clinical trial
Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Phase II Trial of Transdermal Estradiol in Patients With Hormone Refractory Prostate Cancer
Status: Terminated, Estimated PCD: 2008-12-01
Product
Transdermal Estradiol
Clinical trial
Phase II Randomized Study of Docetaxel With or Without Thalidomide in Patients With Androgen-Independent Metastatic Prostate Cancer
Status: Completed
Drug
docetaxel
Drug
thalidomide
Clinical trial
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT and Dynamic Dosimetry With Registered Ultrasound and Fluoroscopy for Localized Prostate Cancer
Status: Recruiting, Estimated PCD: 2028-12-01
Product
(18F)DCFPyL
Clinical trial
A Single Arm, Phase 2 Trial of External Beam Radiation Therapy (EBRT) in Combination With 177Lu-DOTA-TLX591-CHO in Patients With Biochemically Recurrent Oligometastatic, Prostate Specific Membrane Antigen-Expressing Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-07-30
Clinical trial
A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair
Status: Active (not recruiting), Estimated PCD: 2027-07-01
Product
TMZ
Clinical trial
Phase I Trial of Real-Time Intraoperative Fluorescent Imaging of Nerve Structures Using Illuminare-1, A Novel Myelin-Binding Fluorophore
Status: Recruiting, Estimated PCD: 2025-10-04
Product
Illuminare-1
Clinical trial
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
Status: Recruiting, Estimated PCD: 2025-12-31
Drug
ADI-PEG 20
Clinical trial
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
Status: Not yet recruiting, Estimated PCD: 2026-01-31
Product
Technetium Tc 99M Medronate
Clinical trial
A Phase II Trial of Hypofractionated Radiation Therapy for Prostate Cancer With High Risk Features After Radical Prostatectomy
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-03-01
Product
177Lu-PSMA-0057
Clinical trial
Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT): A Phase II Randomized Trial for Intermediate and High Risk Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Transdermal estrogen
Clinical trial
Tolerability of Concurrent EBRT + Lu-PSMA for Node-positive Prostate Cancer (PROQURE-1)
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Randomized Phase II Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Status: Active (not recruiting), Estimated PCD: 2023-12-05
Product
Vemurafenib
Clinical trial
A Pragmatic Phase II Study Evaluating Tolerability in Prostate Cancer Patients Treated With Abiraterone + Prednisone or Darolutamide
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
CHARIOT: A Phase 1b/2 Study of Androgen Deprivation Therapy and Copanlisib in High-Risk Localized Prostate Cancer Patients Prior to Radical Prostatectomy
Status: Recruiting, Estimated PCD: 2027-01-01
Product
Copanlisib
Clinical trial
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and Nivolumab in Patients With Non-Metastatic, PSA-Recurrent Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2022-12-05
Product
pTVG-HP
Drug
T-VEC
Drug
GM-CSF
Clinical trial
Assessing Physical Function Following Androgen Receptor Signaling Inhibitor Treatment for Metastatic Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-10-12
Product
Androgen Receptor Signaling Inhibitors
Clinical trial
Prospective Study of Stereotactic Body Radiotherapy (SBRT) Following Radical Prostatectomy
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Pilot Study for Detection of PSMA-Low Castration Resistant and Neuroendocrine Prostate Cancer With 18F-fluciclovine PET/CT Imaging
Status: Not yet recruiting, Estimated PCD: 2026-09-01
Product
18F-fluciclovine
Clinical trial
A Phase 2 Study of M1774 in Refractory SPOP-Mutant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-04-25
Product
Tuvusertib
Clinical trial
Randomized Phase II Study of Combination Androgen Deprivation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer: Stereotactic Body Radiotherapy vs conventionAl IMRT to Prostate and Pelvic Nodes (SRAM Study)
Status: Recruiting, Estimated PCD: 2024-12-31
Product
SBRT
Clinical trial
Prothrombin Complex Concentrate and Fresh Frozen Plasma in Viscoelastic Test-based Goal-directed Bleeding Management in Non-Cardiac Surgery
Status: Not yet recruiting, Estimated PCD: 2025-04-01
Product
Fresh Frozen Plasma
Product
Prothrombin Complex Concentrate
Clinical trial
Minority-Inclusive Imaging Biomarker-Based End of Therapy Trial for 177Lu-PSMA-617, a Randomized De-Escalation Theranostic Trial for Metastatic Castrate Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2029-12-31
Clinical trial
Systemic Therapy Combined With Cytoreductive Prostatectomy for the Treatment of de Novo Poly-metastatic Hormone Sensitive Prostate Cancer: A Prospective, Open-label Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2028-12-31
Product
Systemic Chemohormonal Therapy
Product
Systemic Hormonal Therapy
Clinical trial
Gadopiclenol (Elucirem): A New Gadolinium Based Contrast Agent With High Relaxivity for Increased Contrast and Improved Differentiation of Clinically Significant Prostate Cancer on Contrast Enhanced MRI: A Prospective Study.
Status: Not yet recruiting, Estimated PCD: 2027-02-01
Product
Gadopiclenol
Clinical trial
A Phase 2 Study of Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
Phase I Study of CART-PSMA-TGFβRDN Cells in Patients With Advanced Castrate Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2038-09-08
Product
CART-PSMA-TGFβRDN
Clinical trial
A Translational Study of Samples From the Radiotherapy and Androgen Deprivation In Combination After Local Surgery (RADICALS) Prostate Cancer Trial to Identify Those Most Likely to Benefit From Androgen Deprivation With Salvage Radiotherapy
Status: Not yet recruiting, Estimated PCD: 2028-08-30
Product
Luteinising Hormone-Releasing Factor Analogue
Clinical trial
Phase I Study Evaluating Extended Field Intensity Modulated Radiation Therapy and Docetaxel in Patients With Prostate Cancer Associated With Pelvic Node Metastasis
Status: Completed, Estimated PCD: 2010-03-09
Drug
bicalutamide
Clinical trial
Randomized Controlled Study on the Efficacy and Safety of Intermittent Darolutamide Treatment in the Triple Therapy of Metastatic Hormone Sensitive Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Prospective Study of Apalutamide and Abiraterone Acetate iN ChemoTHerapy-Naïve mEn With mCRPC Stratified by Race
Status: Active (not recruiting), Estimated PCD: 2025-02-22
Clinical trial
Phase 2 Randomized Trial: Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy (HAMMER)
Status: Recruiting, Estimated PCD: 2027-08-31
Product
BioDFence G3
Clinical trial
A Phase 2 Course Determining Study for Men With Hormone-Naïve Metastatic Prostate Cancer (HNMPCa)
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Study to Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry of ZA-001, an Alpha-particle-emitting (At211) Radiopharmaceutical, in Metastatic Castration Resistant Prostate Cancer
Status: , Estimated PCD: 2025-04-15
Product
ZA-001
Clinical trial
ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.
Status: Terminated, Estimated PCD: 2021-06-28
Product
ODM-201
Clinical trial
Phase II Clinical Trial of Green Tea Catechins in Men on Active Surveillance (AS)
Status: Recruiting, Estimated PCD: 2025-06-30
Product
Sunphenon
Clinical trial
Clinical Study on 68Ga-PSMA-33 for PET/CT Imaging of Prostate Cancer
Status: Recruiting, Estimated PCD: 2023-10-01
Product
68Ga-PSMA-33
Clinical trial
Study of Stereotactic Body Radiotherapy (SBRT) for High-Risk Localized Prostrate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-27
Clinical trial
A Prospective Observational Cohort Study of Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2026-06-23
Product
Standard of care
Product
M7824
Clinical trial
Radiation Enhancement of Local and Systemic Anti-Prostate Cancer Immune Responses
Status: Terminated, Estimated PCD: 2022-09-01
Clinical trial
Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II
Status: Active (not recruiting), Estimated PCD: 2016-11-29
Clinical trial
Phase I Dose-Escalation Trial of 225Ac-J591 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2021-01-07
Clinical trial
Phase I/ll Dose-escalation Study of Fractionated Dose 177Lu-PSMA-617 for Progressive Metastatic Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2021-09-30
Product
68Ga-PSMA-HBED-CC
Clinical trial
A Phase II Trial of Licorice Root and Docetaxel in Patients With Hormone Refractory Prostate Cancer
Status: Terminated, Estimated PCD: 2008-05-01
Clinical trial
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA X CD28) in Patients With High-Risk, Localized Prostate Cancer Followed by Radical Prostatectomy
Status: Recruiting, Estimated PCD: 2024-06-15
Product
REGN5678
Product
Piflufolastat F18
Clinical trial
Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions
Status: Completed, Estimated PCD: 2022-10-03
Product
[Ga-68]PSMA
Clinical trial
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE): A Phase II Randomized Trial
Status: Completed, Estimated PCD: 2023-07-28
Product
Hormone therapy or chemotherapy
Clinical trial
Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer.
Status: , Estimated PCD: 2023-09-30
Product
68Ga-PSMA
Clinical trial
An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients
Status: Recruiting, Estimated PCD: 2028-09-28
Product
Luteinising Hormone Releasing Hormone agonist
Clinical trial
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Status: Completed, Estimated PCD: 2022-08-09
Clinical trial
Nivolumab as a Non-Castrating Therapy for MMR-deficient and CDK12- Altered Prostate Cancer With PSA Recurrence After Local Therapy
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Olaparib in Prostate Cancer Patients With Evidence of Homologous Recombination Deficiency as Assessed Using an Integrated Genomic Signature
Status: Terminated, Estimated PCD: 2023-10-15
Product
Degarelix & Relugolix
Product
ADT + Docetaxel
Product
ADT + Abiraterone + Prednisone
Product
ADT + Abiraterone + Methylprednisolone
Product
ADT + Apalutamide
Product
ADT + Enzalutamide
Clinical trial
The Use of Preoperative Osmotic Laxatives to Improve Recovery of Bowel Function After Robotic-assisted Urologic Surgery
Status: Recruiting, Estimated PCD: 2025-03-02
Product
Polyethylene Glycol 3350
Clinical trial
Lutetium-177-PSMA-617 Radioligand Therapy in Oligo-metastatic Hormone Sensitive Prostate Cancer.
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
Phase 2 Study of CJNJ-67652000 (Niraparib/Abiraterone Acetate Fixed-Dose Combination) and Prednisone for Metastatic Castration-Resistant Prostate Cancer Associated With SPOP Mutation With or Without Homologous Recombination Deficiency
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Abiraterone Acetate + Niraparib
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Trial of Curcumin to Prevent Progression of Biopsy Proven, Low-risk Localized Prostate Cancer Patients Undergoing Active Surveillance
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate
Status: Terminated
Product
Alendronate
Product
ketoconazole
Clinical trial
Phase I/II Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Status: Completed, Estimated PCD: 2023-06-20
Product
Tylenol
Clinical trial
Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer
Status: , Estimated PCD: 2025-03-01
Product
Microdevice
Clinical trial
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
Combination of Darolutamide and Stereotactic Body Radiation Therapy in Patients With Castration Resistant Prostate Cancer and Oligometastases on Functional Imaging
Status: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Randomized, Open-label, Multicenter, Parallel Group Treatment, Phase 3, Two-arm Study to Measure the Effect on Overall Survival and Quality of Life of Immediate Curative Therapy Compared With Standard Conservative Treatment in Older Male Participants Aged ≥ 75 Years With Non-metastatic, High-risk Prostate Cancer
Status: Recruiting, Estimated PCD: 2029-12-31
Clinical trial
A Phase 2 Randomized Open-Label Study of Oral Darolutamide (ODM-201) vs. Androgen Deprivation Therapy (ADT) With LHRH Agonists or Antagonist in Men With Hormone Naive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-01-13
Drug
Etrumadenant
Clinical trial
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Status: Completed, Estimated PCD: 2022-12-22
Product
Androgen deprivation
Clinical trial
A Phase 2 Randomized Trial in Patients With Metastatic Castration Resistant Prostate Cancer to Determine the Efficacy of a Flexible Dosing Schedule of Lu-PSMA Treatment up to 12 Cycles Including Potential Treatment Holiday Periods in Comparison to the Standard Fixed Dosing Schedule of Six Cycles Every Six Weeks (FLEX-MRT)
Status: Not yet recruiting, Estimated PCD: 2027-02-01
Product
Alectinib
Drug
Alpelisib
Clinical trial
A Phase II Study of Enzalutamide Plus Dutasteride/Finasteride as First Line Treatment for Vulnerable Patients ≥ 65 Years With Systemic Prostate Cancer
Status: Completed, Estimated PCD: 2023-10-31
Product
Enzalutamide and Dutasteride
Clinical trial
A Phase 1 Study of JNJ-80038114, a T-Cell Redirecting Agent Targeting Prostate Specific Membrane Antigen (PSMA), for Advanced Stage Prostate Cancer
Status: Completed, Estimated PCD: 2024-03-26
Product
JNJ-80038114
Clinical trial
Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Status: Recruiting, Estimated PCD: 2024-09-30
Product
Anastrozole
Clinical trial
68Ga PSMA-HBED-CC in Intermediate to High-Risk Preprostatectomy Patients
Status: Completed, Estimated PCD: 2021-07-22
Product
Ga-68 PSMA-HBED-CC
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2017-05-19
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME
Status: Terminated, Estimated PCD: 2020-12-10
Drug
olaparib
Clinical trial
Role of Pioglitazone Therapy in Management of Insulin Resistance Associated With Androgen Deprivation Therapy (ADT) in Patients With Prostate Cancer
Status: Withdrawn, Estimated PCD: 2023-03-31
Drug
Varlilumab
Clinical trial
Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Clinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-02-01
Product
Fluoro-2-Deoxy-D-Glucose
Clinical trial
Pentoxifylline, Atorvastatin, and Vitamin E (PAVE) as Treatment for Radiation-Induced Erectile Dysfunction
Status: Completed, Estimated PCD: 2022-11-02
Drug
Atorvastatin
Product
Pentoxifylline
Clinical trial
Immune Activation and Cellular Response From Enzalutamide Alone or With Radium223 in Men With Metastatic, Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-11-21
Clinical trial
Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial
Status: Completed, Estimated PCD: 2018-10-18
Drug
Vitamin D3
Clinical trial
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy, a Randomised Phase II Parallel Cohort Trial
Status: Recruiting, Estimated PCD: 2025-05-01
Product
177Lu-PSMA
Clinical trial
A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partial Nephrectomy
Status: Terminated, Estimated PCD: 2020-03-26
Product
Lidocaine Hydrochloride in Dextrose Solution
Product
0.9% Sodium Chloride
Clinical trial
Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC-RP Trial): A Randomized, Open-label, Multi-centre Phase-2 Study Evaluating the Pathological Complete Response (pCR) Rate Following Neoadjuvant Therapy in Participants With High-risk Prostate Carcinoma for Whom Radical Prostatectomy is Indicated
Status: Completed, Estimated PCD: 2021-05-27
Clinical trial
Phase II Trial of Combination of Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for the Treatment of Intermediate Risk Prostate Cancer
Status: , Estimated PCD: 2026-04-01
Clinical trial
A Phase II Randomized Controlled Trial of a Supplement Containing Quercetin, Bromelain, Rye Flower Pollen, and Papain on Reducing the Severity of Radiation-Induced Prostatitis
Status: , Estimated PCD: 2025-06-01
Product
Q-Urol
Clinical trial
SPECT Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8 ([99mTc]Tc- DB8) in Prostate Cancer and Breast Cancer Patients
Status: Recruiting, Estimated PCD: 2024-06-01
Product
[99mTc]Tc-DB8
Clinical trial
A Phase 2 Study of Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
Durvalumab (MEDI4736) and Olaparib (AZD2281) for Treatment of Biochemically Recurrent Prostate Cancer in Men Predicted to Have a High Neoantigen Load: A Multicenter Pilot Study
Status: Active (not recruiting), Estimated PCD: 2024-06-06
Clinical trial
Phase I/IIa Clinical Trial to Assess the Maximum Tolerated Dose (MTD), Safety, and the Anti-tumor Effect of TB511 Monotherapy and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Product
TB511
Drug
pembrolizumab
Clinical trial
Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk Localized and Locally Advanced Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Pelvic DCFPyL PET-MRI fusion
Clinical trial
A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Status: Completed, Estimated PCD: 2022-03-07
Clinical trial
Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)
Status: Completed, Estimated PCD: 2022-07-27
Clinical trial
A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.
Status: Active (not recruiting), Estimated PCD: 2024-02-19
Drug
Ra223
Clinical trial
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection
Status: Active (not recruiting), Estimated PCD: 2025-11-02
Clinical trial
Phase II, Open-label, Single-center Study Evaluating Safety and Activity of Androgen Deprivation Therapy Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Product
REGN2810
Clinical trial
Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate (POSH-MAP)
Status: Withdrawn, Estimated PCD: 2023-09-22
Clinical trial
A Phase II Randomized Trial of Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Oligometastatic Prostate Cancer (LUST)
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
An Exploratory Study of the Safety and Efficacy of Genomic Biomarker-guided Neoadjuvant Therapy for Locally Advanced and Oligometastatic Prostate Cancer (SEGNO)
Status: Recruiting, Estimated PCD: 2026-04-01
Product
Rezvilutamide
Product
Goserelin Microspheres
Drug
Pamiparib
Product
Tislelizumab
Clinical trial
A Phase I/II Study of High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2021-12-14
Clinical trial
A Phase I/II Study of Hydroxychloroquine and Itraconazole as Therapy for Men With Androgen Normalised Prostate Cancer
Status: Completed, Estimated PCD: 2023-08-30
Product
SUBA-itraconazole
Product
Hydroxychloroquine
Clinical trial
Advanced ChemoHormonal Therapy for Treatment Naïve Metastatic Prostate Cancer: Apalutamide and Abiraterone Acetate With Prednisone and Androgen Deprivation Therapy After Treatment With Docetaxel and Androgen Deprivation Therapy
Status: Active (not recruiting), Estimated PCD: 2028-01-01
Clinical trial
ARRO-CITO: (UMCC 2017.055) Phase Ib/II Single-Arm Multi-Center Study of IONIS-AR-2.5Rx, a Next Generation Androgen Receptor Antisense Oligonucleotide, in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
Status: Terminated, Estimated PCD: 2023-01-24
Product
ARRx
Clinical trial
Phase II Trial of Primary Radiotherapy With Androgen Ablation With or Without Adjuvant Niraparib for Selected High-Risk Locoregional Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-06-07
Clinical trial
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in de Novo Metastatic to Lymph Nodes Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
Luprolide
Clinical trial
A Phase II Multi-Center Trial of Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-20
Clinical trial
A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-05-17
Clinical trial
Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs
Status: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Product
ZM008
Clinical trial
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
Status: Active (not recruiting), Estimated PCD: 2022-07-25
Product
AZD8186
Clinical trial
Open Label Trial of Maintenance Enzalutamide in CRPC
Status: Not yet recruiting, Estimated PCD: 2025-10-31
Clinical trial
Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-06-01
Drug
mFOLFOX6
Product
Androgen receptor pathway inhibitor
Clinical trial
Randomized Phase III Trial of SBRT Versus Hypofractionated Radiotherapy for Salvage of Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma After Radical Prostatectomy
Status: Recruiting, Estimated PCD: 2030-01-22
Clinical trial
A Phase 1b/2 Study of FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-03-31
Drug
FOR46
Product
Pegfilgrastim
Clinical trial
Assessment of the Diagnostic Value of 64Cu-SAR-BBN PET Imaging for Men With Negative PSMA PET in Prostate Cancer
Status: Completed, Estimated PCD: 2023-06-06
Product
Copper-64 labelled SAR-Bombesin
Clinical trial
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: , Estimated PCD: 2018-07-12
Product
AA
Clinical trial
Phase 1 Study of Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With High-risk Stage D1 or Advanced Prostate Cancer
Status: Completed, Estimated PCD: 2006-01-09
Product
NY-ESO-1 protein
Clinical trial
Lowering Cholesterol in Prostate Cancer to Target Rapamycin-Insensitive Companion Of MTOR (TORC2) in T-Cell Surface Glycoprotein CD8 Alpha Chain (CD8+) Lymphocytes
Status: Not yet recruiting, Estimated PCD: 2028-02-29
Product
Vytorin
Clinical trial
A Randomized Trial Comparing Conventional "Salvage" Radiotherapy and Individualized 68Ga-PSMA-11 or 18F-PSMA-1007 PET/CT Targeted Treatment in Patients With Biochemical Recurrence After Prostate Cancer Surgery
Status: Recruiting, Estimated PCD: 2027-10-30
Product
Individualised therapy
Clinical trial
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Status: Active (not recruiting), Estimated PCD: 2026-12-16
Clinical trial
Study of the Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Radionuclide Therapy Prior to Radical Prostatectomy in Men With High-risk Localised Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2022-12-22
Clinical trial
Clinical Trial of a Rapidly Cycling, Non-Cross Reactive Regimen of Approved Therapeutic Agents to Treat Prostate Cancer
Status: Completed, Estimated PCD: 2021-11-15
Product
Radium-223
Drug
cabazitaxel
Clinical trial
Randomized Trial Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
Flutamide
Clinical trial
TRAMP: Tumor Necrosis Factor- α Blockade and AR Inhibition in Men With CRPC
Status: Recruiting, Estimated PCD: 2027-03-31
Product
Golimumab
Clinical trial
Phase I Trial of Concurrent Taxotere With Radiation Therapy and Hormonal Therapy For Clinically Localized High Risk Prostate Cancer
Status: Completed, Estimated PCD: 2011-01-20
Product
GnRh analog
Drug
Celecoxib
Clinical trial
Phase Ib/II Study of Enzalutamide With Venetoclax (ABT-199) in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Status: Completed, Estimated PCD: 2022-07-18
Product
Venetoclax
Clinical trial
An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2023-10-13
Clinical trial
Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy: A Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Oxycodone
Product
Acetaminophen
Clinical trial
A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
Status: Active (not recruiting), Estimated PCD: 2023-12-29
Clinical trial
A Phase 2 Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
Ketorolac
Clinical trial
68Ga-PSMA-11 PET in Patients With Prostate Cancer
Status: Completed, Estimated PCD: 2022-04-14
Product
Ga-PSMA-11
Clinical trial
AtezoCab: A Phase II Study of Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Non-Measurable Disease
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer: a Prospective, Multicenter, Randomized Controlled Clinical Study
Status: Recruiting, Estimated PCD: 2028-03-01
Product
Pioglitazone
Clinical trial
Pilot Clinical Trial of Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-08-31
Drug
Dapagliflozin
Clinical trial
Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
Status: Active (not recruiting), Estimated PCD: 2015-09-20
Clinical trial
A Randomized Trial of High-risK metachroNous oligometastatIc Prostate Cancer With hiGh-risk Mutations Treated witH meTastasiS Directed Therapy and Niraparib/Abiraterone Acetate and Prednisone (KNIGHTS)
Status: Recruiting, Estimated PCD: 2028-12-31
Product
Niraparib + Abiraterone Acetate
Clinical trial
Vitamin D Supplementation in RNA-seq Profiles of Single-core Prostate Samples, Including Diversity and Stress Determinants, Among Veterans
Status: Completed, Estimated PCD: 2022-02-04
Product
cholecalciferol
Clinical trial
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Active (not recruiting), Estimated PCD: 2018-07-17
Product
MK2206
Clinical trial
A Phase I Safety and Feasibility Study of Cellular Immunotherapy for Extensive Stage Small Cell Neuroendocrine Prostate Cancer Using Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptor
Status: Not yet recruiting, Estimated PCD: 2028-03-15
Product
Bendamustine
Drug
fludarabine
Product
T-cell Receptor-engineered T-cells
Clinical trial
Phase 3, Multi-Center, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging Men With Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy With Pelvic Lymph Node Dissection
Status: Recruiting, Estimated PCD: 2025-07-01
Product
Copper Cu 64 PSMA I&T
Clinical trial
Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2026-04-01
Product
Telmisartan
Clinical trial
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Hyperpolarized 13-C-Pyruvate Magnetic Resonance Spectroscopic Imaging Reproducibilty Pilot in Patients With Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Molecular Analysis for Therapy Choice (MATCH)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Strategy to Reduce Bladder Activity With RhPSMA 7.3: Comparison of 18F-RhPSMA 7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2027-07-01
Product
Furosemide
Clinical trial
Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2019-12-01
Product
Afatinib
Clinical trial
A Randomized Phase 2 Trial of White Button Mushroom Supplement in Patients With Biochemically Recurrent Prostate Cancer Following Local Therapy and in Therapy Na?ve Patients With Favorable Risk Prostate Cancer Undergoing Active Surveillance
Status: Recruiting, Estimated PCD: 2024-04-30
Product
White Button Mushroom
Clinical trial
Understanding the Interaction Between Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
High-dose Testosterone in Men With Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 Deficiency
Status: Recruiting, Estimated PCD: 2026-08-31
Product
High dose testosterone
Clinical trial
RecoverPC: A Phase 2 Study of RElugolix Versus GnRH Agonist Quality of Life (QOL) and Testosterone reCOVERy in Men With Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-07-01
Drug
Relugolix
Clinical trial
A Multi-Center Trial of Androgen Suppression With Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS): A Phase I/2 Trial in High Risk and Node Positive Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Prospective Trial of Combination External Beam Radiation Therapy and MRI-guided, Dose-differentiated High Dose-rate Prostate Brachytherapy Boost for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-01-01
Product
Enasidenib
Clinical trial
A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer
Status: Terminated, Estimated PCD: 2012-10-01
Drug
hydroxychloroquine
Product
Binimetinib
Clinical trial
A Single Arm Study of Vidutolimod (CMP-001) With Nivolumab in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-06-23
Product
CMP-001
Clinical trial
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-04-15
Product
AMG 509
Clinical trial
A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)
Status: Active (not recruiting), Estimated PCD: 2024-01-01
Product
Niclosamide
Clinical trial
Phase II Single Arm Study Testing SBRT, Adenosine Signaling Modulation (AB680, AB928), and Immune Checkpoint Inhibition (AB122) for Men With Hormone Sensitive Oligometastatic Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-12-01
Drug
Quemliclustat
Clinical trial
Technology-Enhanced Acceleration of Germline Evaluation for Therapy - The TARGET Study
Status: Active (not recruiting), Estimated PCD: 2024-09-10
Product
Genetic Testing
Clinical trial
Modulation of PSMA Expression in Castration Sensitive and Castration Resistant Prostate Cancer in Response to Hormonal Therapy
Status: Not yet recruiting, Estimated PCD: 2028-09-01
Product
Piflufolastat
Clinical trial
Bipolar Androgen Therapy Plus Olaparib in Patient With Castration-Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2021-03-05
Product
Testosterone Enanthate
Clinical trial
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Status: , Estimated PCD: 2024-11-30
Clinical trial
Detection and Monitoring of Metastasis by 18F-DCFPyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer and Negative, Equivocal, or Oligometastatic Disease on Conventional Imaging (PROSTEP-002)
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Low-dose 500 mg Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer (mCRPC) and Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Patients: a Phase I Proof-of-concept Clinical Study
Status: Active (not recruiting), Estimated PCD: 2023-09-05
Clinical trial
Perioperative Laparoscopic Transversus Abdominis Plane Block During Robotic Assisted Laparoscopic Radical Prostatectomy for Improvement in Postoperative Pain
Status: , Estimated PCD: 2025-08-01
Product
Early TAP Block
Product
Late TAP Block
Clinical trial
COMbination of Bipolar Androgen Therapy and Nivolumab in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2022-10-27
Product
Testosterone cypionate
Clinical trial
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for Adjuvant or Salvage Treatment for Rising PSA After Radical Prostatectomy (EXCALIBUR)
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Phase 2, Randomized, Open-Label, Dose-Finding Study of Debio 4228, an Extended-Release Formulation of Gonadotropin-Releasing Hormone Antagonist in Participants With Locally Advanced/Metastatic Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-03-01
Product
Debio 4228
Clinical trial
Phase II Trial of ArtemiCoffee for Men With Biochemical Recurrence of Prostate Cancer After Initial Local Therapy
Status: Recruiting, Estimated PCD: 2025-12-31
Product
ArtemiCoffee
Clinical trial
A Randomized Phase II Study of Reolysin in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2016-04-26
Product
Docetaxel, Reolysin and Prednisone
Clinical trial
Prospective Study Evaluating the Role of Axumin® (Fluciclovine or 18F-FACBC) PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Fluciclovine
Clinical trial
Safety and Anti-tumor Activity of Lutetium-177 (177Lu)-PSMA-617 Along With Niraparib and Abiraterone Acetate Plus Prednisone in Metastatic Castration Resistant Prostate Cancer - LUNAAR Study
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Product
Niraparib Abiraterone
Clinical trial
Multicentric Phase II Trial of Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS / GETUG P07)
Status: Active (not recruiting), Estimated PCD: 2018-07-24
Product
ELIGARD
Clinical trial
Phase III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging in Patients With Prostate Cancer With Rising PSA Levels [Biochemical Recurrence (BCR)]
Status: Completed, Estimated PCD: 2023-11-23
Product
[68Ga]Ga-PSMA-11
Clinical trial
Evaluating the Effect of ADRB2 Blockers on PKA/BAD/CREB Signaling in Patients Undergoing Prostatectomy
Status: Terminated, Estimated PCD: 2021-06-15
Product
Propranolol
Clinical trial
Drug-drug Interaction Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Subjects With Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2016-11-01
Product
JNJ 56021927
Product
Drug Cocktail
Clinical trial
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
Status: Recruiting, Estimated PCD: 2025-09-30
Drug
Spartalizumab
Clinical trial
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2018-11-02
Drug
enzalutamide
Drug
abiraterone
Drug
prednisone
Product
Rosuvastatin
Clinical trial
Radioligand fOr locAl raDiorecurrent proStaTe cancER
Status: Active (not recruiting), Estimated PCD: 2023-09-25
Product
177Lu-PNT2002
Clinical trial
A First-in-Human, Pilot PET Imaging Study of 89Zr-DFO-YS5, an immunoPET Agent for Detecting CD46 Positive Malignancy in Men With Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Drug
89Zr-DFO-YS5
Product
YS5
Clinical trial
Image-Adapted Target Volumes Using 68Ga-HBED-CC PSMA-PET/MRI for Unfavorable-Risk Prostate Cancer Patients Receiving Radiation
Status: Active (not recruiting), Estimated PCD: 2024-02-07
Clinical trial
Single-Arm Phase II Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Product
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC
Clinical trial
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone (IMPROVE TRIAL): A Randomized, Open Label, Phase II Trial
Status: Terminated, Estimated PCD: 2022-07-01
Clinical trial
Lidocaine Combined With Sufentanil for Preventing Catheter-related Bladder Discomfort After Robot-assisted Radical Prostatectomy: a Randomized, Double-blind, Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2025-09-30
Product
Lidocaine + Sufentanil
Clinical trial
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
Status: Not yet recruiting, Estimated PCD: 2031-01-01
Clinical trial
Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients
Status: Completed, Estimated PCD: 2022-10-10
Product
[68Ga]PSMA
Product
Flourine-18 Sodium Fluoride
Clinical trial
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort
Status: Recruiting, Estimated PCD: 2029-08-27
Drug
LHRHa
Clinical trial
A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-11-30
Product
JNJ-78278343
Clinical trial
A Phase I Study Of Combination Neoadjuvant Hormone Therapy And Weekly OGX-011 (Clusterin Antisense Oligonucleotide) Prior To Radical Prostatectomy In Patients With Localized Prostate Cancer
Status: Completed, Estimated PCD: 2004-09-23
Product
Custirsen
Product
flutamide
Clinical trial
A Phase I/II Clinical Trial of Lenalidomide in Combination With Oral Cyclophosphamide in Patients With Previously Treated Hormone Refractory Prostate Cancer
Status: Terminated, Estimated PCD: 2015-05-19
Drug
lenalidomide
Product
Lutetium-PSMA
Product
Androgen deprivation treatment
Clinical trial
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Status: Recruiting, Estimated PCD: 2026-07-31
Clinical trial
A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Localized Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2028-01-31
Product
Luteinizing Hormone-Releasing Hormone Analog
Clinical trial
ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer
Status: Withdrawn, Estimated PCD: 2025-01-01
Product
Actinium-J591
Clinical trial
Weekly ModraDoc/r in Combination With Hormonal Treatment and High-dose Intensity-modulated Radiation Therapy in Patients With High-risk Early Stage Prostate Cancer
Status: Terminated, Estimated PCD: 2022-02-01
Clinical trial
Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
goserelin
Clinical trial
A Randomized, Double Blind, Placebo Controlled Clinical Trial of L-SeMet Supplementation and Finasteride Treatment of Patients With Prostate Cancer Prior to Robotic Prostatectomy/Brachytherapy
Status: Completed, Estimated PCD: 2012-12-01
Product
finasteride
Clinical trial
A Phase II Study to Evaluate the Performance of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer in Men With an Elevated PSA
Status: Active (not recruiting), Estimated PCD: 2025-03-07
Clinical trial
A Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Phase I Study to Determine the Preferred Dose of the Angiotensin Converting Enzyme Inhibitor Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-01-01
Product
Lisinopril
Clinical trial
[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2024-06-12
Clinical trial
A Phase I, Open-Label, Dose-Finding Study of TVB-2640 Administered in Combination With Enzalutamide (Xtandi) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Recruiting, Estimated PCD: 2025-11-01
Product
TVB-2640
Clinical trial
Phase 1/2 Dose-Escalation and Cohort Study of STEAP1 CART With Enzalutamide in Participants With mCRPC
Status: Not yet recruiting, Estimated PCD: 2027-03-30
Product
Anti-STEAP1 CAR T-cells
Clinical trial
99mTc-PSMA-I&Amp;S in Patients With Prostate Cancer: An Exploratory Biodistribution Study With Histopathology Validation
Status: Recruiting, Estimated PCD: 2024-06-01
Product
99mTc-based PSMA Imaging and Surgery Agent
Clinical trial
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
Status: Not yet recruiting, Estimated PCD: 2027-06-30
Clinical trial
Pilot Study to Identify Radiogenomic Biomarkers to Predict Early Treatment Response to Androgen Deprivation Therapy and Radiation Therapy in High Risk Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Phase 1/2, Open-label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-04-29
Clinical trial
Vorinostat to Augment Response to Lutetium-PSMA-617 in the Treatment of Patients With PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2025-12-30
Product
Vorinostat
Clinical trial
PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2021-07-21
Product
Ga-68 PSMA11
Product
F-18 PSMA 1007
Clinical trial
68Ga-PSMA-11 PET/CT for Screening Prior to 177Lu-PSMA-617 Therapy
Status: Completed, Estimated PCD: 2023-12-31
Product
Gozetotide
Clinical trial
A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2021-08-18
Clinical trial
Dietary Fruit Bioactives and Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2013-08-01
Product
Black Raspberry
Clinical trial
Multi-modality Prostate Cancer Image Guided Interventions - 5
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Phase II Clinical Trial of Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
68Ga-AAZTA-093 PET/CT: First-in-human Study in Patients With Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-07-01
Product
68Ga-AAZTA-093
Product
68Ga-PSMA-11//68Ga-PSMA-617
Clinical trial
Phase II Study of Pembrolizumab in Combination With Radiation With or Without Olaparib in Localized High-risk Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-07-02
Product
Androgen Deprivation
Clinical trial
A Feasibility Study To Determine T-cell Responses To Neoantigens Following Treatment With Ipilimumab In Men With Metastatic Castration-Resistant Prostate Carcinoma
Status: Completed, Estimated PCD: 2019-11-04
Clinical trial
A Randomized Phase II Study of ADT + Abiraterone Versus ADT + Docetaxel + Abiraterone in Patients With Low Volume Metastatic Hormone Sensitive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-05-03
Clinical trial
Syöpäpotilaan Ennusteen Parantaminen Muuttamalla syövän mikroympäristöä ja Metaboliaa Liikunnalla ja lääkkeellisesti - Measuring Oncological Value of Exercise and Statin
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 1, First-in-human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status: Recruiting, Estimated PCD: 2027-09-29
Product
AMX-500
Clinical trial
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
Status: Terminated, Estimated PCD: 2022-07-19
Product
DKN-01
Clinical trial
A Phase II Trial of Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate- and High-Risk Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2020-08-11
Clinical trial
A Pilot Study of rhPSMA-PET MRI Imaging for the Detection of Clinically Actionable Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
Status: Recruiting, Estimated PCD: 2027-06-07
Product
Decipher Prostate Cancer Test
Clinical trial
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD Study)
Status: Recruiting, Estimated PCD: 2026-02-01
Product
Bipolar Androgen Therapy
Clinical trial
A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2024-02-20
Drug
Nab-Paclitaxel
Clinical trial
ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
Status: Active (not recruiting), Estimated PCD: 2026-06-30
Product
GnRH
Clinical trial
Phase IB Study of Personalized Ultrahypofractionated Stereotactic Ablative Radiotherapy of High Risk PROstate Cancer Guided by PET PSMA (68Ga PMSA-11; Ilucix) Response (PULSAR ProPhet)
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Pilot Presurgical Study of Daratumumab (CD38 Antagonist) or JNJ-40346527 in Men With High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy
Status: Completed, Estimated PCD: 2024-01-30
Product
Daratumumab
Product
FMS Inhibitor
Clinical trial
Prevalence of the c.853delT Mutation of the HOXB13 Gene in Prostate Cancer in Martinique
Status: Recruiting, Estimated PCD: 2025-04-09
Product
HOXB13
Clinical trial
A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer With Neuroendocrine Differentiation
Status: Recruiting, Estimated PCD: 2024-11-01
Product
Lutetium Lu 177 Dotatate
Clinical trial
Strength, Aging, and Memory in Prostate Cancer: A Prospective Study of the Effects of Androgen Deprivation on Neurocognition and Frailty
Status: Completed, Estimated PCD: 2023-04-11
Clinical trial
PROstate-specific Membrane Antigen DosImetry-Guided endoradiotherapY: A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy (PRODIGY-1)
Status: Not yet recruiting, Estimated PCD: 2028-06-15
Clinical trial
Phase II Trial of PARP Inhibitor Niraparib for Men With High Risk Prostate Cancer and DNA Damage Response Defects
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase II Trial of In-Situ Autologous Vaccination With Intratumoral and Systemic Hiltonol® (Poly-ICLC) Administered to Prostate Cancer Patients on Active Surveillance
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Poly-ICLC intramuscular injection
Product
Poly-ICLC
Clinical trial
Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Product
APL-5125
Product
Bortezomib
Clinical trial
A Prospective, Multicenter Phase I/II Safety and Tolerability Study of Unilateral Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer
Status: Completed, Estimated PCD: 2012-07-01
Product
WST 11
Clinical trial
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations.
Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Neoadjuvant Phase IIa Study of Ipilimumab {Formerly Known as MDX-010 (BMS-734016)} Plus Hormone Ablation in Men With Prostate Cancer Followed by Radical Prostatectomy.
Status: Completed, Estimated PCD: 2015-10-01
Clinical trial
Clinical Use of 68Ga Prostate Specific Membrane Antigen-11 Positron Emission Tomography With Computed Tomography in Diagnosing, Staging and Restaging Prostate Cancer
Status:
Product
Dabrafenib
Clinical trial
A Prospective, Randomized, Open-label, Multi-centre, Phase II Trial Evaluating IDC/SChLAP1 as a Biomarker for Prediction of Response to Intensified Combined Modality Treatment
Status: Not yet recruiting, Estimated PCD: 2028-12-01
Clinical trial
A Phase 2 Study Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
Dacomitinib
Clinical trial
Phase III Randomized Trial Comparing Short Course Androgen Deprivation Therapy and Ultra-Hypofractionated SBRT Versus SBRT Alone For Intermediate Prostate Cancer
Status: Completed, Estimated PCD: 2023-08-16
Clinical trial
Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Lenvatinib
Clinical trial
A Phase I/II Study of 177Lu-HTK03170 in Metastatic, Castration-Resistant Prostate Cancer Subjects With Prostate-specific Membrane Antigen-positive Disease
Status: Recruiting, Estimated PCD: 2026-03-01
Product
177Lu HTK03170
Product
68Ga-HTK03149
Clinical trial
PROGNOSTIC SIGNIFICANCE OF ENDORECTAL MRI IN PREDICTING OUTCOME AFTER COMBINED RADIATION AND ANDROGEN SUPPRESSION FOR PROSTATE CANCER: A PROSPECTIVE PHASE II STUDY
Status: Completed, Estimated PCD: 2004-01-01
Clinical trial
Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-08-02
Product
PSMA radionuclide therapy
Clinical trial
18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028
Status: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
S2210 A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer With Germline BRCA1/2 Mutations
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Phase III Randomized Study Comparing the Combination of Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With Metastatic Castration-Sensitive Prostrate Cancer (mCSPC)
Status: Withdrawn, Estimated PCD: 2028-12-01
Clinical trial
Comparison of 68 Ga-PSMA Positron Emission Tomography (PET)/CT to Conventional Imaging in Men With High Risk Prostate Cancer
Status: Completed, Estimated PCD: 2022-02-26
Clinical trial
An Open-Label, Parallel, Phase II Study of Single-Agent Oral ESK981 in Men With Castrate-Resistant Prostate Cancer (CRPC)
Status: Completed, Estimated PCD: 2023-03-15
Product
ESK981
Clinical trial
Precision Medicine in the Prostate Cancer Care Pathway: an Evaluation of Integrating Germline Genetic Testing Into the Management of Men at Risk of / Living With Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Prostate cancer risk gene panel
Product
pTVG-AR
Clinical trial
An Open-Label, Phase 1/2, Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Patients With Progressive Advanced Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2012-08-01
Clinical trial
Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopathy of Unknown Significance (MGUS), Low-risk Smoldering Multiple Myeloma (SMM) or Early Stage Prostate Cancer: A Pilot Study
Status: Recruiting, Estimated PCD: 2024-05-31
Product
Curcumin + Piperine
Drug
Ketamine
Clinical trial
A Phase I Study of Neoadjuvant Chemotherapy Involving Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Followed by Surgery for Patients With High Risk Localized Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Advanced Molecular Imaging With Anti-3-[18F]FACBC PET-CT to Improve the Selection and Outcomes of Prostate Cancer Patients Receiving Post-prostatectomy Radiotherapy
Status: Completed, Estimated PCD: 2022-04-18
Product
FACBC
Product
Depo-Eligard
Clinical trial
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/ 3 Trial
Status: Recruiting, Estimated PCD: 2030-07-31
Product
Firmagon
Clinical trial
Relapse in Previously Irradiated Prostate Bed : a Phase I/II Study of Stereotactic Ablative Reirradiation Potentiated by Metformin
Status: Recruiting, Estimated PCD: 2028-11-01
Clinical trial
A Phase II Study of SB939 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2015-01-05
Product
SB939
Clinical trial
A Multinational, Multicenter, Prospective, Randomized, Controlled, Open Label Phase 3 Study With Best Standard of Care With and Without 177Lu-DOTA-rosopatamab for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug
Status: Recruiting, Estimated PCD: 2025-11-01
Product
Standard of Care
Clinical trial
Bipolar Androgen Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study
Status: Completed, Estimated PCD: 2018-02-01
Product
Perflutren Lipid Microsphere
Clinical trial
A Phase Ia/Ib Study of Talazoparib in Combination With Tazemetostat in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status: Active (not recruiting), Estimated PCD: 2025-03-30
Clinical trial
ARN-509+Abiraterone Acetate+Leuprolide With Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study
Status: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
Docetaxel Alone or in Combination With Enzalutamide as First-line Treatment for Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone: a Single Center, Randomized, Open-label Study
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase I/II Study of Enzalutamide in Combination With Indomethacin in Castration-Resistant Prostate Cancer (CRPC)
Status: Recruiting, Estimated PCD: 2024-03-01
Product
Indomethacin
Clinical trial
A Single Arm Study of 6-Months Neoadjuvant Apalutamide Prior to Radical Prostatectomy in Intermediate Risk Patients to Reduce the Frequency of Pathologic Features That Drive Post-Operative Radiation Therapy
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Clinical trial
Phase 2 Trial Pembrolizumab or Pembrolizumab in Combination With Intratumoral SD-101 Therapy in Patients With Hormone-Naïve Oligometastatic Prostate Cancer Receiving Stereotactic Body Radiation Therapy and Intermittent Androgen Deprivation Therapy
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Product
SD-101
Clinical trial
Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carboplatin Induction Chemotherapy in Men With Aggressive Variant Prostate Cancer (AVPC)
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2026-03-31
Clinical trial
68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Prospective Pilot Study Investigating rhPSMA 7.3 PET/MRI in Detecting Recurrent Disease and Aid in Radiotherapy Planning in Patients With Biochemically Recurrent Prostate Cancer
Status: Completed, Estimated PCD: 2024-06-04
Product
Fluorine F 18 rhPSMA-7.3
Clinical trial
A Phase II Study of the Use of MRI-defined Focal Boosts With Stereotactic Body Radiotherapy for Localized Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Randomized, Placebo Controlled Proof of Principle (Window of Opportunity) Study of Hydroxychloroquine (HCQ) in Prostate Cancer Patients Undergoing Radical Prostatectomy
Status: Not yet recruiting, Estimated PCD: 2028-06-01
Product
Hydroxychloroquine Sulfate
Clinical trial
A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in China Participants With Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
Non-Invasive Biomarkers in Prostate Cancer Disease Management
Status: Recruiting, Estimated PCD: 2029-01-31
Product
Genomic and Histological Evaluation
Clinical trial
Remimazolam Versus Propofol for General Anesthesia Induction in Patients on Renin-angiotensin System Blockers Undergoing Robot-assisted Laparoscopic Prostatectomy: A Randomized Controlled Study
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Product
remimazolam
Product
Propofol
Clinical trial
Phase I Trial of Weekly Cabazitaxel With Concurrent Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy for the Treatment of Locally Advanced High Risk Adenocarcinoma of the Prostate
Status: Completed, Estimated PCD: 2015-07-21
Product
Luteinizing Hormone-Releasing Hormone
Clinical trial
Treatment Protocol With BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy: A Prospective Open Label Single-Center Study
Status: Withdrawn, Estimated PCD: 2023-12-31
Clinical trial
Precision Neoadjuvant Therapy for High Risk Localized Prostate Cancer With PTEN Loss
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Drug
pembrolizumab
Product
Short-term androgen deprivation therapy
Product
Capivasertib
Clinical trial
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study
Status: Recruiting, Estimated PCD: 2026-12-01
Product
18F-rhPSMA-7.3
Clinical trial
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Engineered autologous T cells
Clinical trial
A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Zolpidem
Clinical trial
A Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
N-803
Product
MVA-BN-Brachyury
Product
FPV-Brachyury
Product
Epacadostat
Clinical trial
A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-31
Product
BG-68501
Clinical trial
68Ga-RM2 PET/CT for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer
Status: Completed, Estimated PCD: 2021-12-19
Product
Gallium Ga 68-labeled GRPR Antagonist
Clinical trial
A Single-Arm, Open-Label, Phase II Study of Systemic and Tumor Directed Therapy for Recurrent Oligometastatic M1 Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase II Study Of BAY 43-9006 (NSC 724772; CTEP IND# 69,896) In Patients With Hormone Refractory Prostate Cancer
Status: Completed, Estimated PCD: 2006-09-28
Product
Sorafenib
Clinical trial
Prospective Study of the Effect of Androgen Deprivation Therapy (ADT) in Male Patients Suffered Prostate Cancer in Asian Population
Status: Active (not recruiting), Estimated PCD: 2025-10-31
Product
Androgen deprivation therapy - GnRH agonist
Product
Androgen deprivation therapy - GnRH antagonist
Clinical trial
A Phase 2 Study of Neratinib in Patients With Metastatic Castration Resistant Prostate Cancer and Increased Human Epithelial Growth Factor Receptor 2 (HER2) Signaling
Status: Withdrawn, Estimated PCD: 2021-09-24
Product
Neratinib
Clinical trial
A Multi-Center Phase II Study Testing the Activity of Olaparib and AZD6738 (ATR Inhibitor) in Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-01-26
Drug
Ceralasertib
Clinical trial
Phase I/II Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Product
Ivuxolimab
Product
Utomilumab
Clinical trial
A Phase III, Multicenter, Randomized, Controlled Study of Neoadjuvant LHRH-agonist Therapy and Permanent I-125 Implantation With vs. Without Adjuvant LHRH-agonist Therapy in Patients With Untreated Intermediate-risk Prostate Cancer.
Status: Completed, Estimated PCD: 2022-04-24
Product
Adjuvant therapy
Product
Neoadjuvant therapy
Clinical trial
Randomized Assessment of Patients With Clinically Suspected Prostate Cancer After Multiparametric Metabolic Hybrid Imaging to Evaluate Its Potential Clinical Domain: A Prospective, Randomized, Multi-arm, Multi-treatment Clinical Trial
Status: Completed, Estimated PCD: 2022-05-01
Product
68Ga- PSMA-HBED-CC
Clinical trial
Brief Physician-Initiated Quit Smoking Strategies for Clinical Oncology Settings
Status: , Estimated PCD: 2002-02-01
Product
nicotine
Clinical trial
A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Status: Active (not recruiting), Estimated PCD: 2020-04-09
Clinical trial
A Randomized Phase II Study of OGX-011 in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Hormone Refractory Prostate Cancer
Status: Completed, Estimated PCD: 2007-11-08
Clinical trial
Erdafitinib Plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer
Status: Terminated, Estimated PCD: 2021-06-06
Product
Erdafitinib
Clinical trial
A Phase I Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel
Status: Completed, Estimated PCD: 2006-03-09
Clinical trial
A Pilot Study of Stereotactic Body Radiotherapy (SBRT) and 177Lu-PSMA-617 for the Treatment of Hormone Sensitive, Oligometastatic Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
Oral Docetaxel
Clinical trial
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, ADT, Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON): A Phase II, Single Arm, Single Institution Study
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-10-02
Product
PSA
Clinical trial
A Prospective Randomized Controlled Study Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the Treatment of Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase II Study of Weekly Paclitaxel by 1-HR Infusion Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma
Status: , Estimated PCD: 2005-04-01
Product
Estramustine
Drug
paclitaxel
Clinical trial
Duration of Enzalutamide and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Head-to-head Comparison of [68Ga]Ga-PSMA-D5 With [68Ga]Ga-PSMA-11 PET/CT in Prostate Cancer Diagnosis, Recurrence, and Metastasis: a Prospective Study
Status: Recruiting, Estimated PCD: 2024-07-31
Product
[68Ga]Ga-PSMA-D5
Clinical trial
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Product
LHRH Analogue
Clinical trial
Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or Other HRD+ Solid Tumors
Status: Terminated, Estimated PCD: 2024-05-22
Product
TNG348
Clinical trial
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Intermediate Risk Prostate Cancer.
Status: Active (not recruiting), Estimated PCD: 2020-11-02
Product
TOOKAD Soluble
Clinical trial
Phase I/II Study of 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer
Status: , Estimated PCD: 2024-12-24
Drug
177Lu-PSMA-I&T
Clinical trial
Prostate Medication, Metabolism and Gut Microbiota
Status: Recruiting, Estimated PCD: 2024-10-31
Product
Prostate hyperplasia medication
Product
LhRH-antagonist
Clinical trial
Biodistribution and Reproducibility of Ga-68 PSMA-HBED-CC Positron Emission Tomography in Patients With Biopsy Proven Metastatic Prostate Cancer
Status: , Estimated PCD: 2022-12-01
Product
(68Ga)PSMA-HBED-CC
Clinical trial
A Phase I Investigator-initiated Clinical Trial of a Novel Targeted Alpha Therapy for Patients With Castration-resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-03-31
Product
PSW-1025
Clinical trial
Gallium-68 Citrate PET To Detect MYC Amplification in Metastatic Castrate Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2023-06-15
Product
Gallium-68 citrate
Clinical trial
Effect of Dutasteride on Androgen-Response Gene Expression During the Tumor Regrowth Phase of Intermittent Androgen Ablation Therapy in Patients With Advanced Prostate Cancer
Status: Completed, Estimated PCD: 2013-05-01
Clinical trial
Phase II Study of Bicalutamide and Dutasteride for Prostate Cytoreduction Prior to Permanent Implant I-125 Prostate Brachytherapy
Status: Completed, Estimated PCD: 2019-03-01
Product
LHRH agonist + Bicalutamide
Product
Bicalutamide + Dutasteride + Tamoxifen
Clinical trial
The Role of 68Gallium PSMA-11 in Biochemical Recurrence in Prostate Cancer and in Known Metastatic Prostate Cancer and in the Evaluation of Treatment Response After Salvage Therapy
Status: Withdrawn, Estimated PCD: 2023-04-05
Product
68Ga PSMA-11
Clinical trial
18F-DCFPyL PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-risk Prostate Cancer
Status:
Product
F18-DCFPyL
Product
Gadolinium
Clinical trial
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer: An Open-label, Randomized, Cross-Over Trial.
Status: Terminated, Estimated PCD: 2023-10-16
Product
Hyperpolarized Bicarbonate
Clinical trial
ECOG Laboratory Study: Mapping Interactive Cancer Susceptibility Loci
Status: , Estimated PCD: 2007-12-01
Product
Gene Mapping
Clinical trial
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-04-01
Product
Abiraterone Acetate
Clinical trial
Risk Stratified De-Escalated De-Intensified Treatment for High Risk Prostate Cancer Patients Based on Pathologic Criteria, Genetic Score, and Biologic Imaging
Status: Recruiting, Estimated PCD: 2027-04-22
Product
Gonadotropin-releasing Hormone Analog
Clinical trial
A Randomized, Phase II Trial of Brief Androgen-Ablation Combined With Cell-based CG1940/CG8711 Immunotherapy For Prostate Cancer in Patients With Non-Metastatic, Biochemically Relapsed Prostate Cancer
Status:
Product
GVAX prostate cancer vaccine
Clinical trial
Phase I/II Study to Evaluate the Safety and Tolerability, Radiation Dosimetry and Pharmacokinetics, and Efficacy of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-12-01
Product
[177Lu]Lu-XT033
Product
177Lu-XT033
Clinical trial
A Phase 1b Clinical Trial: Improving Outcomes With Androgen Pathway Inhibitors by Targeting DNA Methyltransferase Activity
Status: Recruiting, Estimated PCD: 2025-01-30
Product
Decitabine and Cedazuridine
Clinical trial
Phase 2 Open Label Study of Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
Status: Completed, Estimated PCD: 2023-09-28
Clinical trial
A Phase II Study Assessing the Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-12-30
Product
Testosterone Undecanoate
Clinical trial
A PhaseI/II Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of L-377202 Administered Once Every 3 Weeks
Status: Completed, Estimated PCD: 2000-09-01
Product
L-377202
Clinical trial
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Status: Active (not recruiting), Estimated PCD: 2028-05-31
Clinical trial
Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer
Status: Completed, Estimated PCD: 2004-08-10
Product
Dendritic Cells
Clinical trial
A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents
Status: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
ANZadapt: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-11-10
Clinical trial
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
Poly(ADP Ribose) Polymerase 1
Clinical trial
Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer
Status:
Clinical trial
A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination With Olaparib in Patients With BRCA1/2-Mutant Tumors
Status: Withdrawn, Estimated PCD: 2026-12-06
Product
Magrolimab
Clinical trial
A Randomized Phase I Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer
Status: Completed, Estimated PCD: 2008-02-01
Product
Androderm
Clinical trial
Plasma Amyloid-beta 42/40 to Predict Cognitive Decline From Androgen Deprivation Therapy in Prostate Cancer: a Prospective Observational Study
Status: Recruiting, Estimated PCD: 2026-05-31
Product
Blood-based assay
Clinical trial
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2015-01-13
Product
PX-866
Clinical trial
68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer
Status:
Product
68 Ga-PSMA-11
Clinical trial
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-06-20
Product
TRPV6 Calcium Channel Inhibitor SOR-C13
Clinical trial
Windows Trial of INsulin-like Growth Factor Neutralising Antibody Xentuzumab in MEN Scheduled for Radical Prostatectomy (WINGMEN)
Status: Active (not recruiting), Estimated PCD: 2023-01-31
Product
Xentuzumab
Clinical trial
Randomized, Multicenter Study Comparing the Immediate Adjuvant Radiotherapy Associate With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) vs Delayed Radiotherapy Until Biochemical Relapse Associated With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) in Patients With Operable Prostate Cancer pT3 R1 pN0 or pNx at Intermediate Risk.
Status: Active (not recruiting), Estimated PCD: 2020-04-01
Drug
triptorelin
Clinical trial
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)
Status: Active (not recruiting), Estimated PCD: 2025-04-05
Clinical trial
Radioablation +/- Hormonotherapy for Prostate Cancer Oligorecurrences (RADIOSA Trial): Potential of Imaging and Biology
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study
Status: Active (not recruiting), Estimated PCD: 2024-02-16
Clinical trial
Study of Serum and Urinary Biomarkers and Radiation Cystitis in Patients Treated With Radiotherapy for Localized Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Biological sample collection
Clinical trial
Effect of Neoadjuvant Degarelix on MRI-guided Transurethral Ultrasound Ablation (TULSA) in Patients With Intermediate-risk Prostate Cancer: A Pilot Study
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Pilot Presurgical Study of Daratumumab (CD38 Antagonist) in Men With High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy
Status: Withdrawn, Estimated PCD: 2019-03-01
Clinical trial
Study Of Epoetin Alfa Vs Epoetin Alfa With Dexamethasone In Hormone Refractory Prostate Cancer Patients: Impact On Fatigue, Anemia, Functional Status And Quality Of Life
Status: , Estimated PCD: 2006-06-01
Drug
epoetin alfa
Drug
dexamethasone
Clinical trial
SPECTRA: SupraPhysiological Androgen to Enhance Chemotherapy TReatment Activity
Status: Recruiting, Estimated PCD: 2027-03-31
Product
Etoposide
Clinical trial
Phase 2 INSPIRE Trial: Ipilimumab With Nivolumab for Molecular- Selected Patients With Castration-resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-15
Drug
Lurbinectedin
Clinical trial
Prostate Specific Membrane Antigen (PSMA) Scan and Multiparametric MRI for Prostate Biopsy Detection of Clinically Significant Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Product
18F- DCFPyl
Clinical trial
Stereotactic Prostate Radiotherapy With or Without Androgen Deprivation Therapy, a Phase III, Multi-institutional Randomized-controlled Trial. The SPA Trial.
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Pilot Study of Atorvastatin on Prevention of Metabolic Syndrome in Subjects With Prostate Cancer on Long Term Androgen-deprivation Therapy
Status: Withdrawn, Estimated PCD: 2013-02-01
Product
Atorvastatin
Clinical trial
Phase II Open, Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2022-02-02
Clinical trial
68Ga-PSMA, N,N'-Bis(2-hydroxybenzyl)Ethylenediamine-N,N'-Diacetic Acid (HBED)-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated
Status: Active (not recruiting), Estimated PCD: 2020-10-09
Product
68Ga- PSMA
Clinical trial
An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2019-04-10
Clinical trial
Comparison of the Detection Efficiencies of Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT in Patients With Prostate Cancer
Status: Recruiting, Estimated PCD: 2023-05-01
Product
Al18F-PSMA-617
Product
68Ga-PSMA-617
Clinical trial
Multicentric, Prospective, Randomized Controlled Trial Comparing Best Systemic Therapy (BST) With Radical Prostatectomy or BST Alone in the Management of Men With Pauci-metastatic Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2019-12-01
Product
Best systemic therapy
Clinical trial
The Effect of Androgen Deprivation Therapy on Regulation of Muscle Protein Metabolism and Blood Glucose
Status: Terminated, Estimated PCD: 2023-03-02
Clinical trial
Effect of a Reduced Dose on Cognitive Side Effects of Enzalutamide in Frail (Metastatic) Castration-resistant Prostate Cancer Patients (REDOSE)
Status: Active (not recruiting), Estimated PCD: 2023-03-23
Clinical trial
Multiple-Arm Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb20717 in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-12-16
Product
Vudalimab
Clinical trial
A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed Tumors
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA Radioligand Infusions in Treatment-Naïve Prostate Cancer Patients
Status: Completed, Estimated PCD: 2023-03-22
Product
Gallium Ga-labeled PSMA-11
Clinical trial
The BARCODE 1 Pilot Study: The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening
Status: Active (not recruiting), Estimated PCD: 2018-04-14
Clinical trial
Phase 2 Trial Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Status: Active (not recruiting), Estimated PCD: 2025-07-23
Clinical trial
Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer
Status: Completed, Estimated PCD: 2020-12-31
Product
Adenovirus/PSA Vaccine
Clinical trial
A Study Comparing Intermittent Androgen Depriving Therapy With Or Without Salvage High-Dose Intensity Modulation Radiotherapy (IG-IMRT)To Oligometastatic Pelvic Lymph Nodes In Biochemically-relapsing Prostate Cancer Patients.
Status: Active (not recruiting), Estimated PCD: 2026-06-01
Product
IADT
Clinical trial
A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2016-06-27
Product
JNJ-56021927
Clinical trial
A Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) Versus Paclitaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients With a Rising PSA After Hormonal Therapy for Prostate Cancer
Status: , Estimated PCD: 2004-12-01
Clinical trial
Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes
Status: Active (not recruiting), Estimated PCD: 2025-05-31
Product
Fluciclovine F18
Clinical trial
A First-in-Human, Phase I PET Imaging Study of 11C-YJH08, a Selective Glucocorticoid Receptor-Targeting Agent, in Patients With Advanced Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-10-31
Product
11C-YJH08
Clinical trial
A Phase 1 Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2019-07-09
Clinical trial
99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer and Compared With 68Ga-PSMA-11 PET
Status: Recruiting, Estimated PCD: 2025-06-30
Product
99mTc-QULIC-5-P1
Clinical trial
Intra-operative Optical Imaging Utilizing Anti-PSMA (Prostate Specific Membrane Antigen) Fluorescent Antibody During Robotic Assisted Laparoscopic Prostatectomy
Status: Completed, Estimated PCD: 2018-05-10
Product
MDX1201
Clinical trial
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) as a Response Monitoring Tool in Patients With High-Risk Prostate Cancer Receiving Neoadjuvant Therapy
Status: Not yet recruiting, Estimated PCD: 2027-07-31
Product
Hyperpolarized pyruvate
Clinical trial
Phenotyping Study of CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Types of Solid Tumours With Midazolam
Status: Completed, Estimated PCD: 2022-12-02
Clinical trial
Real World Clinical Practice Study to Assess the Feasibility and Impact of Liquid Biopsy-based Genomic Profiling on Treatment Decision Making for Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)
Status: Recruiting, Estimated PCD: 2026-03-28
Product
Liquid Biopsy
Product
Archival Tumor DNA sequencing
Clinical trial
The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer
Status: Completed, Estimated PCD: 2021-09-09
Clinical trial
PEACE V: A Randomized Phase II Trial for the Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM)
Status: Active (not recruiting), Estimated PCD: 2023-04-30
Clinical trial
Local Cytoreductive Treatments for Men With Newly Diagnosed Metastatic Prostate Cancer in Addition to Standard of Care Treatment
Status: Recruiting, Estimated PCD: 2026-08-31
Clinical trial
Tranexamic Acid's Effects in Patients Undergoing Laparoscopic Radical Prostatectomy: a Randomized, Double-blind, Placebo-controlled Trial
Status: Not yet recruiting, Estimated PCD: 2024-04-01
Product
Tranexamic acid
Clinical trial
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Patients With Metastatic Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-07-01
Product
[18F]FluorThanatrace
Clinical trial
The Impact of Adjuvant Androgen Deprivation Following Radical Prostatectomy on Prostate Cancer Recurrence
Status: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Status: Completed, Estimated PCD: 2022-12-01
Clinical trial
A Phase II Study of Radium-223 in Combination With Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2017-07-01
Product
Radium-223 + Enzalutamide
Clinical trial
A Phase II Randomized Open Label Study of Sipuleucel-T vs. Sipuleucel-T and Tasquinimod in Patients With Metastatic Castrate-Resistant Prostate Cancer (CRPC)
Status: , Estimated PCD: 2015-07-01
Product
Tasquinimod
Clinical trial
A Pilot Study of Neoadjuvant Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer
Status: Terminated, Estimated PCD: 2023-01-15
Product
131I-PSMA-1095
Clinical trial
A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
Status: Active (not recruiting), Estimated PCD: 2024-04-18
Product
Sacituzumab Govitecan
Clinical trial
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
Status: Active (not recruiting), Estimated PCD: 2026-12-01
Clinical trial
A Study of Erdafitinib in Castration-Resistant Prostate Cancer Patients Evaluating Markers of Bone Remodeling and FGF Signaling in Plasma and Bone Marrow
Status: Active (not recruiting), Estimated PCD: 2026-06-30
Clinical trial
PROVENT: A Randomised, Double Blind, Placebo Controlled Feasibility Study to Examine the Clinical Effectiveness of Aspirin and/or Vitamin D3 to Prevent Disease Progression in Men on Active Surveillance for Prostate Cancer
Status: Completed, Estimated PCD: 2020-03-31
Product
Aspirin + Vitamin D
Product
High dose Aspirin
Clinical trial
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
Status: Withdrawn, Estimated PCD: 2022-09-26
Clinical trial
Insulin Resistance in Men With Prostate Cancer on Androgen Deprivation Therapy
Status: Withdrawn, Estimated PCD: 2023-01-18
Clinical trial
A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-prostatectomy Radiation Therapy (COPORT)
Status: Active (not recruiting), Estimated PCD: 2020-12-01
Product
Optional androgen deprivation therapy
Clinical trial
Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer
Status: , Estimated PCD: 2002-06-01
Product
Fowlpox virus vaccine
Product
Recombinant Vaccinia Prostate-Specific Antigen Vaccine
Clinical trial
Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Status: Completed, Estimated PCD: 2021-08-09
Clinical trial
A Phase II Study Comparing Salvage Radiotherapy in Combination With 6 Months of Androgen-deprivation Therapy Versus Anti-androgen Therapy With Apalutamide in Patients With Biochemical Progression After Radical Prostatectomy
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Leuprorelin Acetate
Clinical trial
68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans
Status: Completed, Estimated PCD: 2021-07-21
Product
68Ga-RM2
Clinical trial
PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Placebo-Controlled Trial of Urolithin a Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase II Study of Olaparib and Durvalumab in Men With Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair
Status: Terminated, Estimated PCD: 2023-07-06
Clinical trial
Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2021-08-01
Clinical trial
68Ga-PSMA-11 PET in Patients With Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-09-30
Product
Gallium Ga 68 Gozetotide
Clinical trial
177Lu-labeled NY108 SPECT Imaging in Patients
Status: Recruiting, Estimated PCD: 2024-03-03
Product
NY108
Clinical trial
177-Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (Lunar)
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
Lutetium Lu-177 PNT2002
Clinical trial
The Role of Therapeutic Layering of Stereotactic Body Radiotherapy on Darolutamide in the Management of Oligoprogressive Castration Resistant Prostate Cancer: A Pilot Phase II Trial
Status: Recruiting, Estimated PCD: 2027-11-01
Clinical trial
Molecular Imaging With Ga-68 DOTATATE PET to Investigate Neuroendocrine Differentiation in Prostate Cancer Patients
Status: Completed, Estimated PCD: 2023-02-06
Product
Gallium Ga 68-DOTATATE
Clinical trial
A Phase 2 Comparison Study of 68Ga-PSMA-HBED-CC Positron Emission Tomography (PET)/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer
Status: Terminated, Estimated PCD: 2021-05-05
Product
Gallium-68 labeled PSMA-HBED-CC
Clinical trial
Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts
Status: Completed, Estimated PCD: 2019-11-14
Product
huJ591
Clinical trial
The Role of Akkermansia Muciniphilia in Combating the Metabolic Effects of Androgen Deprivation Therapy in Men With Metastatic Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Product
Apple Cider Vinegar
Clinical trial
A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of ACE-86225106 as Monotherapy in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2028-12-21
Product
ACE-86225106
Clinical trial
T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-02-28
Product
Simvastatin
Clinical trial
Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
Status: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases
Status: Recruiting, Estimated PCD: 2025-04-01
Product
89Sr
Clinical trial
A Randomized Phase II Trial of Mitoxantrone, Estramustine and Navelbine or 13-cis Retinoic Acid, Interferon and Paclitaxel in Patients With Metatstatic Hormone Refractory Prostate Cancer
Status: , Estimated PCD: 2004-07-01
Product
Recombinant Interferon Alfa
Drug
isotretinoin
Product
Mitoxantrone
Clinical trial
A Phase III Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2034-03-01
Clinical trial
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2025-12-01
Product
ETX-19477
Clinical trial
The Registry to Observe Clinical Outcomes of Patients With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Product
Androgen-deprivation Therapy
Clinical trial
A Randomized, Phase II Study Assessing Axitinib as Pre-Surgical Therapy in Patients With High Risk Prostate Cancer
Status: Completed, Estimated PCD: 2013-10-09
Drug
axitinib
Clinical trial
Biomarker Study Targeting Abiraterone Metabolites and Polymporphisms in Men With PSA Progression on Abiraterone for the Treatment of Castration Resistant or Castration Sensitive Prostate Cancer (The Bio-STAMP Study)
Status: Withdrawn, Estimated PCD: 2030-01-01
Clinical trial
A Randomized Phase 2 Trial of Ascorbic Acid in Combination With Docetaxel in Men With Metastatic Prostate Cancer
Status: Terminated, Estimated PCD: 2021-07-31
Clinical trial
Utility of Ga-68-PSMA-11 in Management of Prostate Cancer
Status: Terminated, Estimated PCD: 2022-04-14
Product
Ga-68-PSMA-11
Clinical trial
In Situ Clonal Heterogeneity in Prostatic Diagnostic Biopsies: Impact on Prostate Cancer Evolution and Clinical Outcome. A Retrospective, Proof of Concept Study
Status: Terminated, Estimated PCD: 2023-01-15
Product
Clonal Heterogeneity Evaluation
Clinical trial
Phase II Prospective Monocentric Study on Prostate Cancer Restaging by Using PET/MR With Innovative Radiotracers
Status: Completed, Estimated PCD: 2022-10-05
Clinical trial
A Prospective Study of Maximal-Cytoreductive Therapies for Patients With de Novo Metastatic Hormone-sensitive Prostate Cancer Who Achieve Oligopersistent Metastases During Systemic Treatment With Apalutamide Plus ADT (CHAMPION Study)
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Drug
apalutamide
Clinical trial
Efficacy and Safety of Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer: A Prospective, Multi-centre Study
Status: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Phase 2 Study of Apalutamide in Active Surveillance Patients
Status: Terminated, Estimated PCD: 2020-02-12
Clinical trial
Mechanism and Predictors of Cardiotoxicity After Prostate Cancer Treatment: A Parallel Cohort and Randomized Trial Comparing Radiation Alone, Radiation Plus Leuprolide, and Radiation Plus Relugolix
Status: Active (not recruiting), Estimated PCD: 2025-01-30
Clinical trial
APalutamide and stEReotactic Body Radiation Therapy for Low Burden Metastatic Hormone senSItive Prostate Cancer, a rANdomized Trial - PERSIAN
Status: Not yet recruiting, Estimated PCD: 2024-09-11
Product
SBRT on all sites of metastatic disease+Apalutamide
Clinical trial
Pilot Study of Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With Metastases-directed Stereotactic Body Radiation Therapy (SBRT) With and Without Concomitant Androgen Deprivation Therapy
Status: Recruiting, Estimated PCD: 2023-12-01
Product
Immune Evaluation
Clinical trial
An Open-label, Randomized Study to Assess the Relative Bioavailability (BA) and Bioequivalence (BE) of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2021-10-15
Clinical trial
Phase 0 Trial of Presurgical Cholesterol-lowering on Prostate Cancer Cell Growth
Status: Completed, Estimated PCD: 2019-02-28
Product
Ezetimibe + Simvastatin
Drug
FDG
Clinical trial
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With Metastatic Castrate Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Short Versus Long-term Androgen Deprivation Therapy Combined With Salvage Radiotherapy in Prostate Cancer Patients With Biochemical Recurrence After Prostatectomy: a Multicentre Phase III Randomised Controlled Trial
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Investigation of the Sensitivity and Specificity of 68Ga-HBED-CC-PSMA PET/CT in Prostate Cancer
Status: , Estimated PCD: 2025-01-01
Clinical trial
A Randomized Non-comparative Phase II Multicentric Trial on Short Term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Darolutamide + EBRT
Product
Association of ADT and EBRT
Clinical trial
Observational and Prospective Study on the Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy (GenBx)
Status: Recruiting, Estimated PCD: 2024-12-13
Product
Genetic Assessment
Clinical trial
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
Status: Active (not recruiting), Estimated PCD: 2023-04-07
Product
GnRH analog
Clinical trial
Adjuvant Androgen Deprivation Therapy Combined With Apalutamide for Prostate Cancer Patients Post Radical-prostatectomy With High-risk of Reoccurrence: a Prospective, Single-arm, Multicenter Trial (ARES Study)
Status: Not yet recruiting, Estimated PCD: 2026-08-31
Clinical trial
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)
Status: , Estimated PCD: 2028-01-30
Product
Gonadotrophin Releasing Hormone
Clinical trial
A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
Status: Recruiting, Estimated PCD: 2032-12-31
Product
Sinecatechins
Clinical trial
Clinical Accuracy Assessment of 68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction
Status: Active (not recruiting), Estimated PCD: 2018-11-29
Product
Romidepsin
Clinical trial
A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2018-10-02
Clinical trial
Phase 2, Multicenter, Prospective Cohort Study, Estimating the Efficacy of Focused HIFU Therapy in Patients With Localized Intermediate Risk Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-09-28
Product
Blood Test
Product
Urine test
Clinical trial
Insulin Resistance Following Androgen Deprivation Therapy in Men With Prostate Cancer
Status: Withdrawn, Estimated PCD: 2023-03-29
Clinical trial
RAD 2003/XUAB2104: Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Product
Flibanserin
Clinical trial
Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
A Study of Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18F-DCFPyL
Status: Recruiting, Estimated PCD: 2024-12-31
Product
18F-DCFpyL
Clinical trial
Recommended Dose Estimation of BP-C2 in Patients With Prostate Cancer: A Phase I Dose-finding Study.
Status: Recruiting, Estimated PCD: 2024-08-01
Product
BP-C2
Product
Minnelide
Clinical trial
Comparison of Changes in Tumor Burden (Toral Tumor Volume [TMTV] and Total Lesion Activity [TLA]) in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in the Monitoring of Metastatic Castration-resistant Prostate Cancer Treated With 177Lutetium-PSMA-617
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET/CT in Prostate Cancer Diagnosis, Recurrence, and Metastasis: a Prospective Study
Status: Recruiting, Estimated PCD: 2025-06-30
Product
[18F]F-PSMA-N5
Product
[18F]F-PSMA-1007
Clinical trial
Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in Prostate Cancer Diagnosis, Recurrence, and Metastasis: a Prospective Study
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature
Status: Not yet recruiting, Estimated PCD: 2027-06-30
Clinical trial
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Therapy (Alone or in Combination) or Radiotherapy on the Primary Tumor in Combination With Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: Multicenter Observational Study of Patients Undergoing Treatment in Clinical Practice in Italian Hospitals
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
Status: Recruiting, Estimated PCD: 2025-12-31
Product
68Ga-RM26
Clinical trial
Phase II Single-arm Study Evaluating Neo-adjuvant (Pre-radical Radiotherapy) Abiraterone Acetate (Plus Prednisolone) and Gonadotropin-Releasing Hormone (GnRH) Agonist in High Risk Localised Prostate Carcinoma
Status: Completed, Estimated PCD: 2021-01-19
Clinical trial
A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
P-PSMA-101 CAR-T cells
Clinical trial
A Phase 1b Study Evaluating Combinations With PSCA-Targeting Chimeric Antigen Receptor (CAR)-T Cells for Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-08-01
Product
Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
Clinical trial
Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-11-30
Drug
Pacritinib
Clinical trial
A Combination Therapy to Treat Cancer-Related Fatigue - NCI R01
Status: Recruiting, Estimated PCD: 2026-11-30
Clinical trial
Gallium-68 Labelled THP-PSMA for the Clinical Stage and Restage of Prostate Cancer Patients
Status: Completed, Estimated PCD: 2023-03-31
Product
68Ga-Labeled PSMA
Product
Non-labeled PSMA
Clinical trial
Fully Hybrid 18F-PSMA PET/MRI as One-stop Approach for the Diagnosis of Clinically Significant Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2025-07-31
Clinical trial
DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) Carcinomas
Status: Recruiting, Estimated PCD: 2026-12-31
Drug
Valemetostat
Clinical trial
Dynamic Whole Body Positron Emission Tomography/ Magnetic Resonance Imaging
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With or Without Durvalumab (MEDI4736) in Oligometastatic Recurrent Hormone Sensitive Prostate Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2023-12-27
Product
SBRT + Durvalumab
Clinical trial
Phase I Trial of In Situ Gene Therapy for Locally Recurrent Prostate Cancer Following Radiation Therapy Failure Using Sodium/Iodide Symporter and Radioiodine
Status: Terminated, Estimated PCD: 2018-02-07
Product
Ad5-CMV-NIS
Product
Liothyronine
Product
Reverse Transcriptase-Polymerase Chain Reaction
Clinical trial
Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men With Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy or Radical Prostatectomy
Status: Active (not recruiting), Estimated PCD: 2024-02-06
Product
18F-PSMA
Clinical trial
A Phase I/II Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer
Status: Completed, Estimated PCD: 2023-05-02
Product
89Zr-DFO-MSTP2109A
Product
89Zr DFO-MSTP2109A
Clinical trial
CHemotherapy Plus Enzalutamide In First Line Therapy for Castration Resistant prOstate caNcer
Status: Completed, Estimated PCD: 2018-04-01
Clinical trial
Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-06-21
Product
JNJ-87189401
Clinical trial
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Phase II Trial of Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
Status: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT-00420) in Combination With Androgen Receptor Signaling Inhibitors (ARSIs) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Status: Recruiting, Estimated PCD: 2027-06-01
Drug
Tinengotinib
Clinical trial
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Product
LY4052031
Clinical trial
A Randomized, Open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
Status: Active (not recruiting), Estimated PCD: 2028-11-30
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20187
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20267
Product
Exercise under inhalation CO2
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20255
Abstract
https://www.abstractsonline.com/pp8/#!/20272/presentation/11401
Abstract
https://www.abstractsonline.com/pp8/#!/20272/presentation/11404
Product
SYNC-T therapy: SV-102 + anti-PD-1 mAb + anti-CTLA4 mAb + CD40 agonist mAb + TLR9 agonist CpG-ODN
Clinical trial
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF 06952229 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS
Status: Terminated, Estimated PCD: 2022-03-30
Product
PF-06952229
Clinical trial
68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence
Status: Completed, Estimated PCD: 2019-07-23
Product
Ga-68 PSMA-HBED-CC PET
Clinical trial
a New Spark in Treating Oligorecurrent Prostate Cancer: Adding Systemic Treatment to Stereotactic Body Radiotherapy or Metastasectomy: Key to Long-lasting Event-free Survival?
Status: Recruiting, Estimated PCD: 2027-04-25
Product
Androgen receptor targeted therapy
Product
68Ga-RM26-RGD
Clinical trial
A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Status: Active (not recruiting), Estimated PCD: 2021-06-30
Clinical trial
A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Palliative Radiation Therapy in Patients With Metastatic Cancer
Status: Completed, Estimated PCD: 2018-05-01
Product
Sodium Selenite
Clinical trial
SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer
Status: Recruiting, Estimated PCD: 2030-05-01
Clinical trial
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
Status: , Estimated PCD: 2025-12-31
Product
18F-NaF
Clinical trial
A Safety Trial of Enzalutamide in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)
Status: Completed, Estimated PCD: 2022-01-14
Clinical trial
Dietary Fiber During Radiotherapy and Intestinal Inflammation - a Placebo-controlled Randomized Trial (FIDURA)
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Dietary fiber capsules
Clinical trial
A Single-Arm, Open-Label, Two-Stage Phase II Study of the MEK 1/2 Inhibitor Trametinib in Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-01-31
Product
Trametinib
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
Oxybutynin
Clinical trial
Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Leuprorelin
Clinical trial
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2026-03-01
Product
Zoledronic Acid
Product
Oestradiol
Clinical trial
The Impact of DNA Repair Pathway Alterations Identified by Circulating Tumor DNA on Sensitivity to Radium-223 in Bone Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Radium Ra 223 Dichloride
Clinical trial
Monitoring the Neurological Toxicity of Enzalumatide Through VigiBase, a Pharmacovigilance Study
Status: Completed, Estimated PCD: 2023-01-01
Clinical trial
A Phase 2 Randomized Discontinuation Trial in Patients With Hormone-Dependent Rising Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer Evaluating the Synergy of Metformin Plus Aspirin (PRIMA Trial)
Status: Terminated, Estimated PCD: 2019-12-01
Clinical trial
Hypoxia and Stem Cell Content as Aggression Factors in Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2028-01-01
Product
Pimonidazole
Clinical trial
Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Status: Completed, Estimated PCD: 2018-11-30
Product
Rilimogene Galvacirepvec
Clinical trial
A Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3
Status: Completed, Estimated PCD: 2023-05-03
Product
AZD5363
Clinical trial
A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-03
Product
JNJ-75229414
Product
Bridging Therapy
Clinical trial
A Phase 3, Multi-Center, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Men With Biochemical Recurrence of Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Detection of ISUP≥2 Prostate Cancers Using Multiparametric MRI: Prospective Multicenter Comparison of the PI-RADS Score and an Artificial Intelligence System
Status: Recruiting, Estimated PCD: 2026-06-15
Product
Blood sample
Clinical trial
Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer: a Randomized Phase II Trial (DART)
Status: Recruiting, Estimated PCD: 2026-02-12
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Participants With Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)
Status: Active (not recruiting), Estimated PCD: 2024-09-05
Clinical trial
A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Perioperative Propranolol in Robotic Assisted Laparoscopic Prostatectomy- A Feasibility Study of Propranolol to Target Perioperative Stress Induced Cancer Progression
Status: Completed, Estimated PCD: 2023-11-28
Product
Decapeptyl
Clinical trial
Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Product
MSB0011359C
Product
CV301
Clinical trial
Description of Relugolix Use in Patients With Prostate Cancer: An Analysis of National Veterans Affairs Health Care Network Data
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
Comeback From Long coursE ADT With RElugolix and Darolutamide in Hormone-sensitive Prostate Cancer (CLEARED)
Status: Not yet recruiting, Estimated PCD: 2028-08-31
Clinical trial
A Phase I/IIa Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-03-31
Product
INR101
Clinical trial
An Open-label, Two-part, Phase 2 Clinical Trial to Investigate the Safety and Diagnostic Performance of uPAR PET Imaging for Non-invasive Classification of ISUP Grades Among Patients With Localised, Untreated Prostate Cancer.
Status: Recruiting, Estimated PCD: 2025-09-01
Product
64Cu-DOTA-AE105
Clinical trial
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
Neoadjuvant Degarelix +/- Apalutamide (ARN-509) Followed by Radical Prostatectomy for Intermediate and High-risk Prostate Cancer: a Randomized, Placebo-controlled Trial
Status: Active (not recruiting), Estimated PCD: 2021-07-01
Clinical trial
Phase II Monocentric Study to Evaluate a Novel Approach for Staging Prostate Cancer Patients by Using a Fully Integrated Hybrid PET/MRI
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Dendritic Cell Vaccination in Combination With Docetaxel for Patients With Cancer Prostate - a Randomized Phase II Study
Status: Completed, Estimated PCD: 2015-08-01
Product
mRNA transfected dendritic cell
Clinical trial
A Phase 3, Multi-center, Single-group, Open-label Study to Evaluate the Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-05-20
Product
DKF-MA102
Product
68Ga-RGD